Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC

19187

Studies in scope

all four open statuses

11790

Recruiting now

open to new participants

2028

Lead sponsors

across recruiting studies

Top sites

Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343

Trials with a site in Beijing

Status

Study

Lead sponsor

Phase

Enrol

Chinese sites

Start

Not yet open

The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE

NCT07306585Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)

DrugHC022

HC Biopharma Inc.

Phase 1

Beijing

2025-12-30

Not yet open

The Correlation Between Obstructive Sleep Apnea-Related Nocturnal Hypoxemia Parameters and Coronary Microvascular Dysfunction: A Prospective Cohort Study (SLEEP-CMD)

NCT07315399OSA - Obstructive Sleep Apnea, Coronary Microvascular Dysfunction (CMD), Coronary Artery Disease (CAD)

Beijing Anzhen Hospital

Observational

560

Beijing

2025-12-30

Recruiting

Comparison of Cumulative Opioid Consumption Between Variable-Rate Feedback Infusion and Fixed-Rate Basal Infusion Modes of Intravenous PCA Following Mixed Surgery

NCT07361822Surgery, Pain Management, Opioid Consumption, Patient-controlled Analgesia

Beijing Tiantan Hospital

Not applicable

1,170

Beijing

2025-12-30

Recruiting

Comparison of the Efficacy and Safety of Fixed-rate Basal Infusion Mode and Time-programmed Decremental Background Infusion Mode of Intravenous PCA Following Mixed Surgery

NCT07375121Surgery, Pain Management, Opioid Consumption, Patient Controlled Analgesia

Beijing Tiantan Hospital

Not applicable

450

Beijing

2025-12-30

Recruiting

The Safety and Efficacy of ZVS106e in the Treatment of IRDs Caused by Biallelic Mutations in ABCA4

NCT07241169Stargardt

DrugZVS203e

Zhongshan Ophthalmic Center, Sun Yat-sen University

Early Phase 1

Beijing, Guangzhou

2025-12-29

Recruiting

A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

NCT07376642Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Suzhou Immunofoco Biotechnology Co., Ltd

Early Phase 1

Beijing, Zhengzhou, Hangzhou

2025-12-29

Recruiting

A Multicenter, Retrospective, Observational Cohort Study on Intravenous Thrombolysis Beyond the Time Window for Acute Ischemic Stroke

NCT07419997Stroke

Xuanwu Hospital, Beijing

Observational

2,600

Beijing

2025-12-29

Recruiting

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

NCT07297329Multiple Myeloma (MM)

DrugsSCTC21C·Bortezomib·Lenalidomide·Dexamethasone

Sinocelltech Ltd.

Phase 3

292

Beijing

2025-12-29

Recruiting

A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07225569Hidradenitis Suppurativa

Sanofi

Phase 2

144

Beijing, Changsha, Hangzhou, Shanghai, Wuhan

2025-12-29

Recruiting

A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases

NCT07143045EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases

DrugZorifertinib

Alpha Biopharma (Jiangsu) Co., Ltd.

Observational

800

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Meizhou

2025-12-29

Recruiting

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

NCT07218809Epithelial Ovarian Cancer

DrugsTorvutatug samrotecan·MIRV·Mirvetuximab Soravtansine·Pegylated liposomal doxorubicin

AstraZeneca

Phase 3

1,100

Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou

2025-12-29

Recruiting

Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.

NCT07172360Active Ankylosing Spondylitis

DrugVC005

Jiangsu vcare pharmaceutical technology co., LTD

Phase 3

420

Beijing

2025-12-26

Recruiting

GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma

NCT07138547Lymphoma

Chinese PLA General Hospital

Phase 1/2

Beijing

2025-12-26

Recruiting

Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients

NCT07266116Systemic Light Chain Amyloidosis

DrugTQB2934

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Phase 1/2

Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Guiyang, Baoding, Harbin

2025-12-26

Recruiting

Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients

NCT07043894Solid Tumors, Hematological Tumor, Children, Adolescent

DrugIpilimumab

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

Beijing

2025-12-25

Active, closed

A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity

NCT07285902Obesity

DrugsHRS9531·Semaglutide

Fujian Shengdi Pharmaceutical Co., Ltd.

Phase 3

572

Beijing, Nanjing

2025-12-25

Recruiting

Prospective Randomized Controlled Clinical Study of Acupoint Application With Gutong Plaster in the Treatment of Moderate to Severe Cancer Pain

NCT07657390Cancer Pains

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1/2

198

Beijing

2025-12-25

Not yet open

Clinical Evaluation of Integrated Chinese-Western Medicine for Infertility With DOR Patients in Women Achieving Natural Pregnancy

NCT07296614Diminished Ovarian Reserve (DOR), Infertility

Peking Union Medical College Hospital

Phase 3

320

Beijing

2025-12-25

Recruiting

68Ga-BCMA PET/CT in Multiple Myeloma

NCT07319897Multiple Myeloma, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Multiple Myeloma and Plasma Cell Neoplasm

Peking University First Hospital

Phase 2/3

300

Beijing, Shijiazhuang, Jilin City

2025-12-25

Recruiting

Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke

NCT06658197Stroke, Ischemic, Stroke, Acute, Thrombosis, Brain, Drug Effect

DrugsAlteplase·Tenecteplase

Xuanwu Hospital, Beijing

Phase 3

850

Beijing

2025-12-25

Not yet open

Cardiovascular Surgery Early Prediction System for AKI :CARDS-AKI Registry

NCT07330453Cardiovascular Surgery

Chinese Academy of Medical Sciences, Fuwai Hospital

Observational

5,000

Beijing

2025-12-25

Recruiting

Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's Syndrome

NCT07350707Cushing s Syndrome

Drug68Ga-Pentixafor

Peking Union Medical College Hospital

Phase 1/2

160

Beijing

2025-12-25

Recruiting

JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.

NCT07284134Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

DrugsJS107·Irinotecan·Docetaxel·Paclitaxel

Shanghai Junshi Bioscience Co., Ltd.

Phase 3

560

Hefei, Beijing, Fuzhou, Lanzhou, Wuwei, Guangzhou, Meizhou, Shantou

2025-12-24

Recruiting

β-alanine in the Treatment of Advanced Hepatocellular Carcinoma

NCT07317414Hepatocellular Carcinoma

DrugsAtezolizumab·Bevacizumab

Peking Union Medical College Hospital

Phase 2

158

Beijing, Nanjing, Xuzhou

2025-12-24

Recruiting

A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

NCT07464912Idiopathic Pulmonary Fibrosis (IPF)

DrugTDI01

Beijing Tide Pharmaceutical Co., Ltd

Phase 3

508

Beijing

2025-12-24

Recruiting

A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy

NCT07235202Pancreatic Ductal Adenocarcinoma (PDAC)

DrugsIrinotecan liposome·Nab-paclitaxel·Capecitabine·Gemcitabine

Shenzhen Majory Biotechnology Co., Ltd.

Phase 1/2

Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Harbin, Zhengzhou

2025-12-24

Active, closed

Extracellular Vesicles for the Treatment of Syringomyelia

NCT07295067Syringomyelia

Xuanwu Hospital, Beijing

Phase 1

Beijing

2025-12-23

Recruiting

Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma

NCT07248956Hypopharyngeal Carcinoma

DrugsAlbumin-Bound Paclitaxel /nab-Paclitaxel·Cisplatin

Eye & ENT Hospital of Fudan University

Phase 2

116

Harbin, Jinan, Beijing, Shanghai, Tianjin

2025-12-22

Recruiting

Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors

NCT07586813Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gastrointestinal Neoplasms, Pancreatic Cancer

DrugsTretinoin·All-trans retinoic acid·ATRA·Ipilimumab

Peking University People's Hospital

Phase 2

220

Beijing

2025-12-22

Recruiting

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

NCT07174336Breast Neoplasms, Neoplasm Metastasis

DrugsTersolisib·Exemestane·Anastrozole·Ribociclib

Eli Lilly and Company

Phase 3

800

Anyang, Beijing, Changchun, Changde, Changsha, Chengdu, Deyang, Fuzhou Fujian

2025-12-22

Not yet open

A Study on the Effectiveness of Preventive Extensive Release of the Rotator Interval and Joint Capsule to Reduce Postoperative Stiffness in Arthroscopic Rotator Cuff Repair

NCT07311616Supraspinatus Tear

Beijing Jishuitan Hospital

Not applicable

Beijing

2025-12-22

Recruiting

Individualized Transcranial Magnetic Stimulation in Parkinsonian Disorders

NCT07570212Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy

Peking University First Hospital

Not applicable

Beijing

2025-12-22

Recruiting

Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors

NCT07586826Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gynecologic Cancers, Ovarian Cancer

DrugsTretinoin·All-trans retinoic acid·ATRA·Ipilimumab

Peking University People's Hospital

Phase 2

220

Beijing

2025-12-22

Recruiting

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT07225946Prostatic Neoplasms, Castration-Resistant

DrugsPasritamig·Prednisone/Prednisolone·Docetaxel

Janssen Research & Development, LLC

Phase 3

800

Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanjing, Shanghai, Tianjin

2025-12-19

Not yet open

A Multicenter Randomized Controlled Trial of Echocardiography-Guided Atrial Septal Defect Closure Performed in a Mobile Surgical Unit

NCT07273227ASD - Atrial Septal Defect

China National Center for Cardiovascular Diseases

Phase 4

300

Beijing

2025-12-19

Active, closed

Efficacy and Safety of Home-based Structured Physical Exercise in Patients With Acute Ischemic Stroke

NCT07271082Acute Ischemic Stroke

Capital Medical University

Not applicable

208

Fuyang, Suzhou, Beijing, Zhoukou, Shihezi

2025-12-18

Recruiting

TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors

NCT07242417Solid Cancer, GPC3 Positive Hepatocellular Carcinoma

DrugsFludarabine·Cyclophosphamide

Beijing GoBroad Hospital

Early Phase 1

Beijing

2025-12-18

Recruiting

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Allogeneic CAR-NK Cell Therapy for Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT07298239Prostate Cancer Castration-resistant Prostate Cancer

DrugAnti-PSMA CAR-NK

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Early Phase 1

Beijing

2025-12-18

By invitation

Safety and Efficacy of Intravenous IDOV-Immune in Patients With Advanced Solid Tumors

NCT07656090Cancer

DrugIDOV-Immune

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Early Phase 1

Beijing

2025-12-18

Recruiting

Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2

NCT07263308Acute Ischemic Stroke

DrugAlbumin

Capital Medical University

Phase 3

1,192

Anqing, Bozhou, Fuyang, Ma’anshan, Suzhou, Wuhu, Beijing, Fuzhou

2025-12-18

Recruiting

A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT07418736Chronic Obstructive Pulmonary Disease

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2

318

Beijing

2025-12-18

Recruiting

PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic Cardiomyopathy

NCT07443696Ischemic Cardiomyopathy, Heart Failure

Sinotau Pharmaceutical Group

Phase 2

Beijing, Tianjin

2025-12-18

Recruiting

Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients

NCT07314294Metastatic Colorectal Cancer

Shanghai EpimAb Biotherapeutics Co., Ltd.

Phase 2

Beijing, Guangzhou

2025-12-18

Recruiting

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

NCT07285460Hemophilia

DrugsAntithrombin·Clotting factor concentrates·Fitusiran

Sanofi

Phase 3

Beijing, Wuhan

2025-12-18

Recruiting

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

NCT07185997Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing

DrugFurmonertinib

ArriVent BioPharma, Inc.

Phase 3

480

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Shantou

2025-12-17

By invitation

Safety, Tolerability, and Preliminary Efficacy of Hepatocyte-like Cell Injection for the Prevention and Treatment of Small-for-Size Syndrome

NCT07276568Small-for-size Syndrome

Zhi-Jun Zhu

Early Phase 1

Beijing

2025-12-17

Recruiting

Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases

NCT07464132Tumor, Cardiovascular Diseases, Pulmonary Fibrosis, Rheumatic Immune Diseases Involving Large Blood Vessels

Drug68Ga-NI-FAPI

Peking Union Medical College Hospital

Phase 1/2

Beijing

2025-12-17

Recruiting

Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors

NCT07280832Unresectable Locally Advanced or Metastatic Melanoma, Unresectable Locally Advanced or Metastatic Urinary Tract Tumors

DrugJMT108

Shanghai JMT-Bio Inc.

Phase 1/2

500

Beijing

2025-12-17

Recruiting

Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid

NCT07311772Nasopharyngeal Cancinoma (NPC), Radiation-induced Oral Mucositis

Sun Yat-sen University

Phase 3

386

Beijing, Fuzhou, Guangzhou, Shantou, Zhuhai, Nanning, Wuzhou, Changsha

2025-12-16

Recruiting

A Phase II Trial of LM103 in Advanced Melanoma

NCT07310784Advanced Melanoma

DrugLM103 TILs

Suzhou BlueHorse Therapeutics Co., Ltd.

Phase 2

Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Changchun

2025-12-16

Recruiting

Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers

NCT07260708Advanced Cancers

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Phase 1

Beijing, Guangzhou, Zhengzhou, Changsha, Nanjing, Nanchang, Dalian, Jinan

2025-12-16

Recruiting

A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors

NCT07228247Solid Tumors, Adult

Hutchmed

Phase 1/2

147

Beijing, Changsha, Guangzhou, Hefei, Shanghai, Shenyang, Zhengzhou

2025-12-16

Recruiting

A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus

NCT07323173Systemic Lupus Erythematosus

Nanjing Leads Biolabs Co.,Ltd

Phase 1

117

Bengbu, Beijing, Guangzhou, Changsha, Nanjing, Pingxiang, Shanghai, Taiyuan

2025-12-16

By invitation

Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase

NCT07383298Chronic Myeloid Leukemia

DrugOlverembatinib

Qian Jiang

Observational

100

Beijing

2025-12-16

Recruiting

The Analgesic Efficacy and Safety of Flurbiprofen Patch in Patients With Herpes Zoster

NCT07370402Herpes Zoster, Pain

DrugFlurbiprofen

Beijing Tiantan Hospital

Not applicable

750

Beijing

2025-12-15

Recruiting

The Analgesic Efficacy and Safety of Baclofen in Patients With Herpes Zoster

NCT07378046Herpes Zoster, Pain

Beijing Tiantan Hospital

Not applicable

750

Beijing

2025-12-15

Recruiting

A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

NCT07276581Rheumatoid Arthritis

AstraZeneca

Phase 2

320

Beijing, Changchun, Changsha, Guangzhou, Jiujiang, Kunming, Linyi, Nanchong

2025-12-15

Recruiting

The Analgesic Efficacy and Safety of Crisugabalin in Patients With Herpes Zoster

NCT07307976Herpes Zoster, Pain

Beijing Tiantan Hospital

Not applicable

750

Beijing

2025-12-15

Recruiting

The Analgesic Efficacy and Safety of Loxoprofen Sodium Patch in Patients With Herpes Zoster

NCT07378059Herpes Zoster, Pain

Beijing Tiantan Hospital

Not applicable

750

Beijing

2025-12-15

Not yet open

Host-Microbe Interactions in Biliary Dilatation

NCT07152496Choledochal Cyst

Beijing Tsinghua Chang Gung Hospital

Observational

400

Beijing

2025-12-15

Recruiting

The Analgesic Efficacy and Safety of Desvenlafaxine in Patients With Herpes Zoster

NCT07361809Herpes Zoster, Pain

Beijing Tiantan Hospital

Not applicable

750

Beijing

2025-12-15

Recruiting

Lidocaine for LESS Postoperative Shoulder Pain Alleviation

NCT07537127Cystectomy, Myomectomy

Peking Union Medical College Hospital

Not applicable

100

Beijing

2025-12-15

Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

NCT07282600Overweight, Obesity

DrugEloralintide

Eli Lilly and Company

Phase 3

1,035

Beijing, Chengdu, Chongqing, Guangzhou, Hefei, Jinan, Luoyang Shi, Nanchang

2025-12-15

By invitation

Extension Study of the PUMCH-E101 Clinical Trial：Safety and Efficacy Study of PUMCH-E101 Injection in the Contralateral Eye

NCT07878572Inherited Retinal Diseases

Peking Union Medical College Hospital

Early Phase 1

Beijing

2025-12-15

Recruiting

The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster

NCT07361796Herpes Zoster, Pain, Postherpetic Neuralgia

Beijing Tiantan Hospital

Not applicable

832

Beijing

2025-12-15

Recruiting

The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster

NCT07307170Herpes Zoster, Mirogabalin, Pain

Beijing Tiantan Hospital

Not applicable

750

Beijing

2025-12-15

Recruiting

Humanistic Continuing Care Via WeChat for Patients Undergoing Thermal Ablation of Papillary Thyroid Carcinoma

NCT07302672Papillary Thyroid Carcinoma

Ming-an Yu

Not applicable

108

Beijing

2025-12-15

Recruiting

The Analgesic Efficacy and Safety of Tulodesvenlafaxine in Patients With Herpes Zoster

NCT07370389Herpes Zoster, Pain

Beijing Tiantan Hospital

Not applicable

750

Beijing

2025-12-15

Not yet open

CLEAR Trial: CA330 Cytokine Adsorption Column for Anticoagulant/Antiplatelet Patients in Non-Elective CPB Surgery.

NCT07284199CABG, Aortic Dissection, Valvular Heart Diseases

Beijing Anzhen Hospital

Not applicable

120

Beijing

2025-12-15

Recruiting

A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus

NCT07444307Systemic Lupus Erythematosus (SLE)

Hangzhou Qihan Biotech Co., Ltd.

Phase 1

Hefei, Wuhan, Beijing

2025-12-15

Active, closed

the Exploration of MTAP Deletion in Osteosarcoma by Immunohistochemistry

NCT07593573Osteosarcoma, MTAP Deletion, Immunohistochemistry

Peking University People's Hospital

Observational

100

Beijing

2025-12-15

Recruiting

A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis

NCT07215494Light Chain (AL) Amyloidosis, MRD

Peking University First Hospital

Not applicable

Beijing

2025-12-15

Recruiting

Non-invasive Ultrasound and Hematoma Clearance After Intracerebral Hemorrhage

NCT07246473Intracerebral Hemorrhage

Beijing Tiantan Hospital

Not applicable

Wuhu, Beijing

2025-12-12

Recruiting

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis

DrugsVepugratinib·Pembrolizumab

Eli Lilly and Company

Phase 3

450

Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin

2025-12-12

Active, closed

A Study to Evaluate the Safety and Tolerability of RAG-18 in Pediatric Patients With Duchenne Muscular Dystrophy

NCT07282652Duchenne Muscular Dystrophy (DMD)

Peking Union Medical College Hospital

Early Phase 1

Beijing

2025-12-12

Recruiting

KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer

NCT07481058Esophageal Squamous Cell Carcinoma (ESCC)

DrugsKC1036·Toripalimab·Paclitaxel·Cisplatin

Beijing Konruns Pharmaceutical Co., Ltd.

Phase 2

Beijing

2025-12-12

Active, closed

Cervical Cytology DNA Methylation for Endometrial Cancer Screening

NCT07874529Endometrial Cancer, DNA Methylation, Cytology, Cancer Screening

Lei Li

Observational

30,000

Beijing

2025-12-12

Recruiting

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

NCT07222800Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site

DrugsPF-08634404·Avastin·Bevacizumab

Pfizer

Phase 3

800

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Meizhou, Nanning

2025-12-11

Recruiting

Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection in the Treatment of Adult Upper Limb Spasticity .

NCT07242300Upper Limb Spasticity (ULS)

DrugRecombinant Botulinum Toxin Type A

JHM BioPharma (Tonghua) Co. , Ltd.

Phase 3

207

Bengbu, Hefei, Beijing, Chongqing, Guangzhou, Nanning, Cangzhou, Shijiazhuang

2025-12-11

Active, closed

A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)

NCT07223723Amyotrophic Lateral Sclerosis

DrugTofersen

Biogen

Phase 4

Beijing

2025-12-11

Recruiting

A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+

NCT07326215Acute Respiratory Distress Syndrome, Acute Kidney Injury

Vantive Health LLC

Not applicable

Beijing, Guangzhou, Shenzhen, Harbin, Nanjing, Nanchang, Shanghai, Chengdu

2025-12-11

Recruiting

AI Facial Analysis Algorithm to Screening Coronary Artery Disease in High-Risk Community Population

NCT07277686Coronary Artery Disease (CAD), Artificial Intelligence Algorithms, Face, Screening

China National Center for Cardiovascular Diseases

Observational

1,392

Zhoukou, Beijing

2025-12-11

Recruiting

Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases

NCT07301164System Lupus Erythematosus, Systemic Sclerosis (SSc), Inflammatory Myositis, Antiphospholipid Syndrome

Peking University Third Hospital

Early Phase 1

Beijing

2025-12-11

Recruiting

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

NCT07222267Breast Cancer, Advanced Solid Tumor

DrugBG-75202

BeOne Medicines

Phase 1

Beijing, Chongqing, Xiamen, Guangzhou, Harbin, Changsha, Nanjing, Shanghai

2025-12-11

Recruiting

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

NCT07226349Advanced Solid Tumor

DrugsBGB-43395·Fulvestrant

BeOne Medicines

Phase 1

105

Beijing, Guangzhou, Harbin, Wuhan, Nanjing, Jinan, Weifang

2025-12-11

Recruiting

A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis

NCT07302360Colitis, Ulcerative

Xian-Janssen Pharmaceutical Ltd.

Observational

200

Beijing, Changzhou, Guangzhou, Hangzhou, Nanjing, Shenzhen, Shijiazhuang, Tianjin

2025-12-11

Recruiting

Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)

NCT07265570Ulcerative Colitis

InSilico Medicine Hong Kong Limited

Phase 2

Beijing, Chongqing, Guangzhou, Huizhou, Nanning, Shijiazhuang, Luoyang, Xinxiang

2025-12-10

Recruiting

Near-infrared Light Therapy Device for Mild-Moderate Alzheimer's Disease (NirsCure-03A)

NCT07262645Alzheimer s Disease

Danyang Huichuang Medical Equipment Co., Ltd.

Phase 3

320

Beijing, Shijiazhuang, Baotou, Suzhou, Xi'an, Shanghai, Taiyuan, Tianjin

2025-12-10

Not yet open

Songling Xuemaikang Capsules for Cerebral Small Vessel Disease

NCT07271732Hypertension, Cerebral Small Vessel Diseases

DrugSongling Xuemaikang

Dongzhimen Hospital, Beijing

Not applicable

Beijing

2025-12-10

Recruiting

A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug-coated Stents and the Xience Drug-eluting Stent System in Patients With Acute Coronary Syndrome and High Bleeding Risk Using Optical Coherence Tomography

NCT07230847Coronary Heart Disease, Acute Coronary Syndrome

China National Center for Cardiovascular Diseases

Not applicable

Beijing

2025-12-10

Not yet open

A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia

NCT07297875Achondroplasia

DrugABSK061

Abbisko Therapeutics Co, Ltd

Phase 1/2

110

Beijing, Zhengzhou, Wuhan, Shanghai, Chengde, Chengdu, Hangzhou

2025-12-10

Not yet open

Gait and Paraspinal sEMG in Degenerative Spinal Diseases

NCT07309926Adult Spinal Deformity, Degenerative Scoliosis, Sagittal Deformity, Sagittal Imbalance

Xuanwu Hospital, Beijing

Observational

120

Beijing

2025-12-10

Not yet open

Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer

NCT07277452Pancreatic Cancer, Adult

DrugNimotuzumab

The First Affiliated Hospital with Nanjing Medical University

Phase 2

156

Nanjing, Beijing

2025-12-10

Recruiting

The Impact of Image-Assisted Colonoscope on Patient Experience, Physician Workload, and Examination Quality

NCT07541924Colorectal Cancer Screening, Colonic Polyps/Colonoscopy/Colorectal Neoplasms, Difficult Colonoscopy, Colonoscopy-Related Discomfort

DONG WU

Not applicable

200

Beijing

2025-12-09

By invitation

Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer

NCT07386704Pancreatic Cancer Non-resectable

DrugNimotuzumab

Peking University First Hospital

Phase 2

Beijing

2025-12-09

Recruiting

A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension

NCT07654140Uncontrolled Hypertension

DrugSAL0140

Shenzhen Salubris Pharmaceuticals Co., Ltd.

Phase 2

252

Beijing

2025-12-09

Recruiting

A Clinical Study of Glycerol Phenylbutyrate in Chinese Patients With Urea Cycle Disorders

NCT06904027Urea Cycle Disorders

DrugRavicti

Tongji Hospital

Observational

Beijing, Guangzhou, Wuhan, Shanghai, Hangzhou

2025-12-09

Recruiting

A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia

NCT07269210Severe Hypertriglyceridemia

Eli Lilly and Company

Phase 2

Beijing, Chengdu, Guangzhou, Luoyang, Shanghai, Xuzhou

2025-12-08

Recruiting

NWRD06 DNA Plasmid for HCC After Curative Resection.

NCT07324304Hepatocellular Carcinoma (HCC)

Newish Technology (Beijing) Co., Ltd.

Phase 2

Beijing, Harbin, Hangzhou

2025-12-08

Recruiting

A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo

NCT07153666Vitiligo

DrugRuxolitinib

Peking University Third Hospital

Observational

170

Beijing

2025-12-08

Not yet open

Characterising the Network-Specific Effects of Piriform Cortex Stimulation Via SEEG

NCT07305311Refractory Epilepsy, Neuromodulation

Xuanwu Hospital, Beijing

Not applicable

Beijing

2025-12-08

Recruiting

Cilostazol for Preventing Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage

NCT07249853Aneurysmal Subarachnoid Hemorrhage

DrugCilostazol

Beijing Tiantan Hospital

Phase 3

380

Beijing

2025-12-06

Recruiting

A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

NCT07241416Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

DrugsEnzalutamide Soft·Rezvilutamide

Jiangsu HengRui Medicine Co., Ltd.

Phase 3

206

Beijing

2025-12-05

Active, closed

A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease

NCT07211776Thyroid Eye Disease (TED)

DrugVRDN-003

Zai Lab (Shanghai) Co., Ltd.

Phase 3

108

Beijing, Bengbu, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou

2025-12-05

Recruiting

A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies

NCT07173595Relapsed or Refractory Hematologic Malignancies

Qilu Pharmaceutical Co., Ltd.

Phase 1

186

Beijing

2025-12-05

Recruiting

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

NCT07221253Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Durvalumab

AstraZeneca

Phase 3

1,100

Beijing, Changchun, Changde, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou

2025-12-04

Recruiting

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

NCT07262567Metastatic Pancreatic Cancer

DrugCetuximab

Genfleet Therapeutics (Shanghai) Inc.

Phase 3

320

Beijing

2025-12-04

Recruiting

A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

NCT07209111Neoplasm Malignant

DrugsCalderasib·Cetuximab

Merck Sharp & Dohme LLC

Phase 2

150

Beijing, Xiamen, Guangzhou, Harbin, Wuhan, Changsha, Nanjing, Nanchang

2025-12-04

Recruiting

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

NCT07250802Plaque Psoriasis

DrugZasocitinib

Takeda

Phase 3

110

Beijing, Guangzhou, Changsha, Hangzhou, Shanghai

2025-12-04

Recruiting

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

NCT07283835Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer

DrugCretostimogene Grenadenorepvec

Lepu Biopharma Co., Ltd.

Phase 2

Beijing, Chongqing, Fuzhou, Wuhan, Changsha, Nanjing, Shenyang, Jinan

2025-12-04

Recruiting

A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

NCT07255404Pancreatic Ductal Adenocarcinoma (PDAC)

DrugsMFOLFIRINOX·Pumitamig·Nab-paclitaxel·Gemcitabine

BioNTech SE

Phase 2

105

Beijing, Changchun, Chengdu, Dalian, Guangzhou, Hangzhou, Jinan, Kunming

2025-12-04

Recruiting

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

NCT07276399Squamous Cell Carcinoma of Head and Neck

DrugsAmivantamab·Cisplatin·Carboplatin·Pembrolizumab

Janssen Research & Development, LLC

Phase 3

600

Beijing, Bengbu, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Hangzhou

2025-12-03

Recruiting

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors

NCT07371663Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), Gastric (Stomach) Cancer, Endometrial Cancer

Beijing Tide Pharmaceutical Co., Ltd

Phase 1/2

266

Beijing, Zhengzhou, Hangzhou

2025-12-03

Recruiting

A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)

NCT07487727Anemia Due to Chronic Kidney Disease

DrugAND017

Kind Pharmaceuticals LLC

Phase 3

240

Beijing

2025-12-03

Recruiting

Balloon Guide Catheter Combined With Filter Protection for Carotid Artery Stenting

NCT07247864Carotid Artery Stenosis

Beijing Anzhen Hospital

Not applicable

296

Beijing

2025-12-03

Recruiting

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

NCT06979453Plaque Psoriasis

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

366

Beijing, Guangzhou, Shenzhen, Handan, Zhengzhou, Changsha, Jinan, Shanghai

2025-12-03

Recruiting

A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis

NCT07265284Psoriasis

Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

Phase 3

104

Beijing

2025-12-03

Recruiting

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

NCT07218926Gastrointestinal Neoplasms

DrugsIDRX-42·Sunitinib

GlaxoSmithKline

Phase 3

450

Shijiazhuang, Shanghai, Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan

2025-12-03

Recruiting

Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer

NCT07238283First-line Treatment of Metastatic Pancreatic Cancer

Drugs5Fluorouracil·Irinotecan Hydrochloride Liposome·Calcium folinate·Nab-paclitaxel

Jiangsu HengRui Medicine Co., Ltd.

Phase 3

662

Beijing

2025-12-02

Recruiting

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

NCT06807281Atopic Dermatitis

DrugAbrocitinib

Pfizer

Phase 3

450

Beijing, Shenzhen, Changsha, Nanchang, Hangzhou, Shanghai

2025-12-02

Recruiting

PTC-Guided Therapy for Peritoneal Mesothelioma

NCT07330271Peritoneal Mesothelioma

Beijing Tsinghua Chang Gung Hospital

Not applicable

347

Beijing

2025-12-02

Recruiting

A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)

NCT07116031Chronic Graft Versus Host Disease

DrugBelumosudil

Sanofi

Phase 2

Beijing, Shanghai, Shenzhen, Suzhou

2025-12-02

Recruiting

Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

NCT07165951Metastatic Pancreatic Ductal Adenocarcinoma

DrugsTQB2868·Anlotinib hydrochloride·Gemcitabine·Paclitaxel

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Phase 3

566

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen

2025-12-02

Recruiting

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

NCT07201558Rheumatoid Arthritis, Systemic Lupus Erythematosus

DrugSurovatamig

AstraZeneca

Phase 1

Beijing, Chengdu, Nanjing

2025-12-02

Recruiting

FAPI PET Imaging in Nonischemic Cardiomyopathy

NCT07878338Nonischemic Cardiomyopathy

Peking Union Medical College Hospital

Phase 2

400

Beijing

2025-12-02

Active, closed

A Study of DII235 in Adults With Elevated Lipoprotein(a)

NCT07235046Lipoprotein Disorder

Novartis Pharmaceuticals

Phase 2

234

Luoyang, Shenyang, Wenzhou, Beijing

2025-12-02

Recruiting

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

NCT06937229Alzheimer Disease, Agitation

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

650

Beijing, Haidian District, Guangzhou, Shenzhen, Changsha, Nanjing, Tianjin, Hangzhou

2025-12-02

Not yet open

For Patients With Myocardial Infarction and Multiple Vessel: Testing if Ultrasound (UFR) Can Guide All Needed Treatment in One Procedure, Avoiding a Return Hospital Visit for a Second Operation.

NCT07264881Microvascular Obstruction (MVO), Multivessel Coronary Artery Disease, ACS (Acute Coronary Syndrome), ST Elevation Myocardial Infarction (STEMI)

Beijing Anzhen Hospital

Observational

200

Beijing

2025-12-02

Recruiting

A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer

NCT07042802Ovarian Cancer

DrugsLBL-024·Paclitaxel·Bevacizumab

Nanjing Leads Biolabs Co.,Ltd

Phase 1/2

180

Beijing, Fuzhou, Guangzhou, Harbin, Anyang, Zhengzhou, Xuzhou, Shenyang

2025-12-02

Recruiting

Eye-Brain-Kidney in CKD

NCT07358572Chronic Kidney Diseases

Beijing Friendship Hospital

Observational

1,500

Beijing

2025-12-01

Recruiting

Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients

NCT06514508Multiple Myeloma

DrugsMotixafortide·G-Csf

Guangzhou Gloria Biosciences Co., Ltd.

Phase 3

Beijing, Harbin

2025-12-01

Recruiting

MPR for Stroke Risk Assessment of ICAS

NCT07309718ICAS - Intracranial Atherosclerosis, Stroke Ischemic, Hemodynamic

Xuanwu Hospital, Beijing

Observational

400

Beijing

2025-12-01

Active, closed

Digital Angiography-Derived Fractional Flow Assessment for Intracranial Stenosis

NCT07309705Intracranial Atherosclerosis ICAS, Hemodynamic, Stroke

Xuanwu Hospital, Beijing

Observational

400

Beijing

2025-12-01

Recruiting

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer

NCT07392346Gastric Cancer Adenocarcinoma Metastatic

DrugsIparomlimab and Tuvonralimab·Fruquintinib·Paclitaxel

Dai, Guanghai

Phase 2

Beijing

2025-12-01

Recruiting

A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery

NCT07182682Non-Small Cell Lung Cancer

DrugSunvozertinib

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Phase 3

360

Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin

2025-12-01

Recruiting

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis

NCT05517980Glomerulonephritis

Kira Pharmacenticals (US), LLC.

Phase 2

Beijing

2025-12-01

Recruiting

Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors

NCT07275853Advanced Solid Tumors

DrugKXV01 TCR Lentinvivo

TCRx Therapeutics Co.Ltd

Phase 1

Beijing

2025-12-01

Recruiting

Intelligent Management Platform for Guiding Exercise Rehabilitation in Coronary Heart Disease Patients

NCT07259278Secondary Prevention of Coronary Heart Disease

China National Center for Cardiovascular Diseases

Not applicable

200

Beijing

2025-12-01

Recruiting

Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Cervicogenic Headache

NCT07347730Myofascial Trigger Points, Cervicogenic Headache, Dorsal Root Ganglion

Beijing Tiantan Hospital

Not applicable

1,036

Beijing

2025-12-01

Not yet open

A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

NCT07200947SMARCA4-Deficient Tumor, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Zhijie Wang

Phase 2

Beijing

2025-12-01

Not yet open

Efficacy and Safety Evaluation of Non-invasive Temporal Interference Stimulation for Blood Pressure Regulation

NCT07239492Hypertension, Hypotension

Xuanwu Hospital, Beijing

Not applicable

Beijing

2025-12-01

Recruiting

Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Shoulder Osteoarthritis(OA)

NCT07347054Myofascial Trigger Points, Chronic Musculoskeletal Pain, Shoulder Osteoarthritis

Beijing Tiantan Hospital

Not applicable

1,036

Beijing

2025-12-01

Recruiting

Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Hip Osteoarthritis(OA)

NCT07347041Myofascial Trigger Points, Chronic Musculoskeletal Pain, Hip Osteoarthritis

Beijing Tiantan Hospital

Not applicable

1,036

Beijing

2025-12-01

Recruiting

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

NCT07241390Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease

DrugOrforglipron

Eli Lilly and Company

Phase 3

7,140

Beijing, Changchun, Changde, Changzhou, Chengdu, Chongqing, Dalian, Guangzhou

2025-12-01

Recruiting

Individualized Application of Anti-Thymocyte Globulin(ATG)in Unrelated Donor Hematopoietic Stem Cell Transplantation

NCT07648992Hematopoietic Stem Cell Transplantation

DrugAnti-Thymocyte Globulin

Daihong Liu

Phase 4

324

Beijing

2025-12-01

Recruiting

Diagnostic Value of 68Ga-Pentixafor PET/CT in Adrenal Tumors With Aldosterone and Cortisol Cosecretion

NCT07605156Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion

Peking University First Hospital

Observational

130

Beijing

2025-12-01

Not yet open

A RCT of Moist Ag Dressing in Chronic Wound

NCT07235254Chronic Wound, Hard to Heal Wounds, Dressing, Wound he'a'Ling

Peking University Third Hospital

Not applicable

Beijing

2025-12-01

Recruiting

Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Migraine

NCT07347067Myofascial Trigger Points, Chronic Migraine Headache, Greater Occipital Nerve Block

Beijing Tiantan Hospital

Not applicable

1,036

Beijing

2025-12-01

Recruiting

A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis

NCT07235384Atopic Dermatitis (AD)

Zai Lab (Shanghai) Co., Ltd.

Phase 1

Beijing, Fuzhou, Nanchang, Jinan, Shanghai, Hangzhou

2025-12-01

Not yet open

Evaluating the Safety and Effectiveness of a Vascular Interventional Robotic System in Assisting With Percutaneous Coronary Intervention Procedures: A Prospective, Multicenter, Randomized Controlled Clinical Trial

NCT07233317Coronary Artery Disease

China National Center for Cardiovascular Diseases

Not applicable

170

Beijing

2025-12-01

Recruiting

Safety and Tolerability Study of a Novel Bioartificial Liver in Liver Failure and Small-for-Size Syndrome

NCT07312864Liver Failure, Small-for-Size Syndrome

Beijing Friendship Hospital

Phase 1/2

Beijing

2025-12-01

Not yet open

A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS

NCT07169175Amyotrophic Lateral Sclerosis (ALS)

DrugSNUG01

SineuGene Therapeutics Co., Ltd.

Phase 1/2

Beijing, Fuzhou, Hangzhou

2025-12-01

Recruiting

Multicenter Randomized Controlled Trial (RCT) and Efficacy Evaluation System Study on Surgical Innovation Strategies for Neonatal Complex Congenital Heart Disease

NCT07363538Complex Congenital Heart Disease

Central China Fuwai Hospital of Zhengzhou University

Not applicable

738

Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Qingdao

2025-12-01

Recruiting

Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia

NCT07297173Relapsed Leukemia, Refractory Leukemia

Beijing 302 Hospital

Phase 1

Beijing

2025-12-01

Recruiting

A Trial of Shengmai Liquid for Long COVID Fatigue.

NCT06980636Long COVID Fatigue

Beijing University of Chinese Medicine

Phase 4

100

Beijing

2025-12-01

Active, closed

Neuromuscular Rehab for ACL Reconstruction: Knee Function & Brain Plasticity

NCT07243860Anterior Cruciate Ligament Injuries

Peking University Third Hospital

Not applicable

Beijing

2025-12-01

Active, closed

Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

NCT07246564Myasthenia Gravis

DrugRozanolixizumab

UCB Biopharma SRL

Phase 4

Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Jinan, Shanghai, Shenzhen

2025-12-01

Recruiting

A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA

NCT07282353Primary Biliary Cholangitis

DrugPleacbo

Cascade Pharmaceuticals, Inc

Phase 3

135

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhanjiang, Nanning

2025-12-01

Active, closed

AI Chatbots for Anxiety Mental Health Literacy

NCT07316374Anxiety Literacy, Anxiety Disorders, Mental Health Literacy

Peking University

Not applicable

200

Beijing

2025-12-01

Not yet open

Application of Quantum Detection-Driven Artificial Intelligence Algorithms for Single-Molecule cfDNA Characterization in the Early Diagnosis of Prostate Cancer

NCT07238959Benign Prostate Hypertrophy(BPH), Prostate Cancer (Diagnosis), Prostate Neoplasm

Shanghai Changzheng Hospital

Observational

1,100

Beijing, Guangzhou, Nanjing, Suzhou, Shanghai, Chengdu, Ningbo

2025-12

Recruiting

TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant Tumors

NCT07266298Solid Metastatic Tumor

Neowise Biotechnology

Phase 1

Beijing

2025-12

Recruiting

A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.

NCT07230483Atopic Dermatitis (AD)

DrugCM512

Keymed Biosciences Co.Ltd

Phase 2

246

Beijing

2025-12

Not yet open

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3217 Tablets in Subjects With Advanced Malignant Tumors

NCT07291050Advanced Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1

Beijing

2025-12

Recruiting

CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT

NCT07441291B ALL, Allogenetic Hematopoietic Stem Cell Transplantation, MRD-positive

DrugCar-T

Peking University People's Hospital

Phase 3

Beijing

2025-11-30

Not yet open

Rehabilitation Exercise Intervention for Rheumatoid Arthritis Patients Using Artificial Intelligence-Based Exercise Prescription System

NCT07246811Rheumatoid Arthritis (RA)

Peking University Third Hospital

Not applicable

147

Beijing

2025-11-30

Not yet open

Transcranial Alternating Current Stimulation for Patients With Mild Alzheimer's Disease II (TRANSFORM-AD II)

NCT07230158Alzheimer Disease

Xuanwu Hospital, Beijing

Not applicable

160

Beijing

2025-11-30

Recruiting

Observational RegIstry of Effectiveness and Safety of teNecTeplase in reAl worLd Settings in China

NCT07271342Stroke

DrugTenecteplase

Beijing Tiantan Hospital

Observational

10,000

Beijing

2025-11-30

Recruiting

A Phase Ⅱa Clinical Study of CL-197 Capsules

NCT07308782HIV-1 Infection

Henan Genuine Biotech Co., Ltd.

Phase 2

Beijing

2025-11-29

Recruiting

The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-management

NCT06909773Cardiovascular Diseases

AstraZeneca

Not applicable

3,000

Anqing, Beijing, Changsha, Chaohu, Chengdu, Chifeng, Chongqing, Dalian

2025-11-28

Active, closed

A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment

NCT07220538Ischemic Stroke Hospitalized, Impairment, Cognitive

Dr. Willmar Schwabe GmbH & Co. KG

Phase 4

400

Anyang, Baotou, Beijing, Benxi, Chenzhou, Chifeng, Dalian, Harbin

2025-11-28

Recruiting

Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting

NCT07236814Influenza

DrugOseltamivir

Capital Medical University

Phase 3

384

Beijing

2025-11-28

Recruiting

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

NCT07189065Diffuse Large B-Cell Lymphoma (DLBCL)

DrugsRocbrutinib·Bendamustine·Lenalidomide·Rituximab

Guangzhou Lupeng Pharmaceutical Company LTD.

Phase 2

150

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Nanning, Shijiazhuang

2025-11-27

Recruiting

Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis

NCT07236099Prurigo Nodularis (PN)

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 2

135

Wuhu, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Jingzhou, Changsha

2025-11-27

Recruiting

A Prediction Model in Pregnant Women With Aplastic Anemia

NCT07101770Aplastic Anemia, Pregnancy, Prediction Model

Peking University People's Hospital

Observational

300

Beijing

2025-11-27

Recruiting

YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC)

NCT07793500NSCLC, Advanced Solid Tumor

DrugYSCH-01

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Early Phase 1

Beijing

2025-11-27

Recruiting

A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib

NCT07362940Non-Small Cell Lung Cancer

DrugsDositinib mesylate·GEN-725

Henan Genuine Biotech Co., Ltd.

Phase 1/2

110

Beijing, Changsha, Jinan, Xiamen, Zhengzhou

2025-11-27

Recruiting

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

NCT06994845Primary Immunoglobulin A Nephropathy (IgAN)

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

Hangzhou, Beijing

2025-11-27

Active, closed

Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

NCT07160608Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Alexion Pharmaceuticals, Inc.

Phase 2

Beijing, Guangzhou, Hangzhou, Nanchang

2025-11-26

Recruiting

Establishment of a Multimodal Standard Database for Inflammation-related Ophthalmopathy

NCT07628946Ocular Surface Disease, Inflammatory Disease, Retinal Disease, Choroid Diseases

Dan Chen

Observational

3,000

Beijing

2025-11-26

Recruiting

A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer

NCT07217301IO Resistant Squamous and Nonsquamous NSCLC

Takeda

Phase 3

1,200

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Harbin, Xinxiang

2025-11-26

Recruiting

Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma

NCT07355699Marginal Zone Lymphoma(MZL)

DrugsOrelabrutinib·Obinutuzumab·Rituximab

Beijing Tongren Hospital

Phase 4

Beijing

2025-11-25

Recruiting

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

NCT07155174Small Cell Lung Cancer

DrugsABBV-706·Lurbinectedin·Etoposide·Atezolizumab

AbbVie

Phase 2

180

Beijing, Zhengzhou, Wuhan, Nanchang, Shanghai, Chengdu

2025-11-25

Active, closed

A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis

NCT07136805Non-infectious Anterior Uveitis

DrugPrednisolone acetate

VivaVision Biotech, Inc

Phase 3

154

Chongqing, Beijing

2025-11-25

Active, closed

Effect of Perception-based Interventions on Public Acceptance of Using Large Language Models in Medicine

NCT07304908Large Language Models, Acceptability of Health Care, Perception, Self

Peking University

Not applicable

3,000

Beijing

2025-11-25

Recruiting

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

NCT07176650Hepatocellular Carcinoma (HCC)

DrugsYervoy·Opdivo

Shanghai Henlius Biotech

Phase 1

246

Beijing, Bengbu, Changchun, Changsha, Chengdu, Dongguan, Fuzhou, Ganzhou

2025-11-25

Not yet open

Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia Syndrome

NCT07240376Non-Allergic Rhinitis With Eosinophilia Syndrome

DrugStapokibart

Huazhong University of Science and Technology

Not applicable

Guangzhou, Wuhan, Xiangyang, Nanchang, Chengdu, Beijing, Shanghai

2025-11-25

Recruiting

Local Methylene Blue Injection for Prevention of Anastomotic Leakage and Permanent Stoma After Low Anterior Resection for Rectal Cancer

NCT07833319Rectal Cancers

DrugMethylene Blue

Peking University Cancer Hospital & Institute

Phase 2

Beijing

2025-11-25

Recruiting

A Phase Ia Clinical Trial of HW241045

NCT07448194Healthy Volunteers, IPF

Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

Phase 1

Beijing

2025-11-24

Not yet open

Subthalamic Nucleus Versus Globus Pallidal Internus Deep Brain Stimulation for Parkinson Disease

NCT07250685PD - Parkinson's Disease

Zhang Jianguo

Not applicable

Beijing, Wuhan, Nanjing, Dalian, Jinan, Shanghai, Tianjin, Hangzhou

2025-11-24

Recruiting

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

NCT07174310Parkinson's Disease

DrugPrasinezumab

Hoffmann-La Roche

Phase 3

900

Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanjing

2025-11-24

Recruiting

FMS-CrossFit Training Program (FCTP) to Improve School Readiness in Preschool Children With Autism Spectrum Disorder

NCT07532395Autism Spectrum Disorder

Peking University

Not applicable

184

Beijing, Fuzhou

2025-11-22

Recruiting

Effect of Visual-Guided Balance Training on Knee Motor Function and Biomechanical Characteristics After ACL Reconstruction

NCT07306221Anterior Cruciate Ligament Injuries

Peking University Third Hospital

Not applicable

Beijing

2025-11-22

Recruiting

Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke

NCT07279493Acute Ischemic Stroke

Kunming Pharmaceuticals, Inc.

Phase 2

300

Beijing, Shenzhen, Cangzhou, Hengshui, Daqing, Anyang, Nanyang, Xuzhou

2025-11-22

Recruiting

A Platform Study of In Vivo CAR-T for Treating Advanced Malignant Tumors Based on Target Screening

NCT07395479Advanced Malignant Tumours

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Early Phase 1

Beijing

2025-11-21

Active, closed

Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

NCT07162883Carcinoma, Non-Small-Cell Lung

DrugsKeytruda·Pembrolizumab

Qilu Pharmaceutical Co., Ltd.

Phase 3

146

Bengbu, Beijing, Chongqing, Lanzhou, Haikou, Zhengzhou, Changsha, Nanjing

2025-11-21

Recruiting

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension

NCT07650084Refractory Chronic Cough

DrugCamlipixant

GlaxoSmithKline

Phase 3

Leshan, Beijing, Changsha, Chengdu, Chongqing, Dongguan, Ganzhou, Guangzhou

2025-11-21

Recruiting

Asymptomatic TB With Innovative Modified Short-course Regimens

NCT06153069Tuberculosis

Huashan Hospital

Phase 4

426

Beijing, Liupanshui, Nayong, Shanghai, Hangzhou

2025-11-21

Recruiting

A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])

NCT07208058Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis

DrugPlonmarlimab

TJ Biopharma Co., Ltd.

Phase 3

Beijing, Guangzhou, Nanning, Shijiazhuang, Zhengzhou, Wuhan, Nanchang, Shenyang

2025-11-21

Recruiting

Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma

NCT07371923Diffuse Large B Cell Lymphoma (DLBCL)

DrugsPola-R-Chp·Zanubrutinib

Beijing Tongren Hospital

Phase 2

Beijing

2025-11-20

Not yet open

Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients

NCT06683131Acute Myocardial Infarction (AMI)

DrugTafolecimab

The Affiliated Hospital of Xuzhou Medical University

Phase 4

1,160

Fuyang, Huai'an, Lianyungang, Nanjing, Suqian, Xuzhou, Beijing, Shanghai

2025-11-20

Recruiting

A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

NCT07216027Atopic Dermatitis, Eczema, Atopic

Pfizer

Phase 2

165

Fuzhou, Guangzhou, Shanghai, Beijing

2025-11-20

Recruiting

A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors

NCT07253116Advanced Solid Tumors

Nanjing Jingao biomidical technology Co. Ltd.

Phase 1/2

Beijing

2025-11-20

Recruiting

The Feasibility Study of Polymer Artificial Heart Valve for the Treatment the Mitral Valve Disease.

NCT07243184Severe Mitral Valve Regurgitation, Severe Mitral Valve Stenosis

Shanghai HeartEpoch Medical Technology Co., Ltd

Not applicable

Beijing

2025-11-19

Recruiting

Neuroendoscopy-assisted Drainage Versus Burr Hole Drainage for Chronic Subdural Hematoma

NCT07144423Chronic Subdural Hematoma

Beijing Tiantan Hospital

Not applicable

770

Beijing, Xiamen, Jiangmen, Shantou, Shenzhen, Liuzhou, Nanning, Wuzhou

2025-11-19

Active, closed

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study

NCT07216976Parkinson's Disease

MedtronicNeuro

Not applicable

Beijing, Guangzhou, Shanghai, Chengdu

2025-11-19

Active, closed

A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome

NCT07211685Alport Syndrome

Bayer

Phase 2

Beijing, Guangzhou, Wuhan, Hangzhou

2025-11-19

Recruiting

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

NCT07228832Metastatic Colorectal Cancer (CRC)

DrugsIvonescimab·Leucovorin·Adrucil·Oxaliplatin

Summit Therapeutics

Phase 3

900

Beijing, Fuzhou, Guangzhou, Foshan, Shenzhen, Zhuhai, Haikou, Shijiazhuang

2025-11-18

Recruiting

A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

NCT07243171Overweight and/or Obesity, Weight Management

DrugEcnoglutide

Hangzhou Sciwind Biosciences Co., Ltd.

Phase 1/2

126

Beijing

2025-11-18

Recruiting

A Phase 1 Study of HDM2017 in Advanced Solid Tumors

NCT07274085Solid Tumors

DrugHDM2017

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Phase 1

Beijing

2025-11-18

By invitation

Clinical Evaluation of [68Ga]Ga-NOTA-RF PET Imaging Targeting RFVT3 in Patients With Pituitary Tumors

NCT07254104Pituitary Neoplasms

Peking Union Medical College Hospital

Early Phase 1

Beijing

2025-11-17

Recruiting

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of SXRN Injection in Patients With Cancer Cachexia

NCT07231120Cachexia-Anorexia Syndrome, Solid Tumor Malignancies

DrugSXRN

Jiangsu Nutai Biologics Co., Ltd

Phase 1

Beijing

2025-11-17

Recruiting

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

NCT07290803Atopic Dermatitis

Sanofi

Observational

1,000

Beijing, Shenzhen, Changsha, Xi’an, Chengdu, Hangzhou, Ningbo, Chongqing

2025-11-17

Recruiting

Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection

NCT07128888Obesity or Overweight

Gan & Lee Pharmaceuticals.

Phase 1

Beijing

2025-11-17

Recruiting

Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China

NCT07161388Limited Stage Small-Cell Lung Cancer

AstraZeneca

Observational

200

Beijing, Cangzhou, Dongguan, Fuzhou, Guangzhou, Huzhou, Jinan, Nanjing

2025-11-17

Recruiting

Weekly Dynamics of Psychopathological and Symptom Networks During Mindfulness-Based Interventions for Emotional Distress

NCT07280481Depression, Anxiety, Emotional Disorders

Peking University

Not applicable

500

Beijing

2025-11-16

Recruiting

GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma

NCT07209813Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer

DrugGKL-006

Beijing Gene Key Life Technology Co., Ltd

Phase 2

Beijing, Zhengzhou, Changsha, Nanjing, Nanchang, Hangzhou

2025-11-14

Recruiting

Comparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR)

NCT07439133Coronary Artery Disease(CAD)

Sinotau Pharmaceutical Group

Phase 3

395

Beijing, Foshan, Tianjin

2025-11-14

Recruiting

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

NCT07219420Palmoplantar Pustulosis

DrugBimekizumab

UCB Biopharma SRL

Phase 3

320

Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Shanghai, Shenzhen

2025-11-14

Recruiting

A Study of DEG6498 in Participants With Solid Tumors

NCT07244835Malignant Neoplasms

Degron Therapeutics Co.

Phase 1

100

Beijing, Guangzhou

2025-11-13

Recruiting

Registry Study of Cerebral Small Vessel Disease

NCT07342075Cerebral Small Vessel Diseases, Cognitive Impairment, Diffusion Tensor Imaging

Dongzhimen Hospital, Beijing

Observational

Beijing

2025-11-13

Recruiting

Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo

NCT07239245Resectable Hepatocellular Carcinoma With High Risk of Recurrence

DrugsAtezolizumab·Bevacizumab

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

Beijing, Zhengzhou, Shenyang, Taiyuan

2025-11-12

Recruiting

A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.

NCT07207070Breast Cancer

DrugsJS105·Dalpiciclib·Fulvestrant

Risen (Suzhou) Pharma Tech Co., Ltd.

Phase 3

312

Beijing, Zhengzhou

2025-11-12

Recruiting

Evaluation of NWRD08 for HPV-16 and/or HPV-18 Related Cervical HSIL

NCT07175662High-grade Squamous Intraepithelial Lesion (HSIL)

Newish Biotech (Wuxi) Co., Ltd.

Phase 2

150

Beijing, Taiyuan

2025-11-11

Recruiting

Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease.

NCT07423013Thyroid Eye Disease

Peking University Third Hospital

Not applicable

Beijing

2025-11-11

Recruiting

AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL

NCT07215585Large B-cell Lymphoma

DrugsR-mini-CHOP·Surovatamig

AstraZeneca

Phase 3

420

Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Haikou

2025-11-11

Recruiting

Real-world Study of Aflibercept 8 mg in nAMD

NCT07640997Neovascular Age-Related Macular Degeneration (nAMD)

DrugAflibercept

Peking University People's Hospital

Observational

300

Beijing, Fuzhou, Shenzhen, Zunyi, Harbin, Nanyang, Wuhan, Hohhot

2025-11-11

Not yet open

Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid

NCT07210554Bullous Pemphigoid (BP)

DrugStapokibart

Chengdu Kangnuoxing Biopharma,Inc.

Phase 3

200

Beijing

2025-11-11

Recruiting

Intravenous Thrombolysis Combined With Tirofiban in Acute Ischemic Stroke

NCT07290751Acute Ischemic Stroke

DrugTirofiban

Beijing Anzhen Hospital

Phase 4

976

Beijing

2025-11-11

Recruiting

Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC

NCT07232654LOCALLY ADVANCED CERVICAL CANCERS

DrugsLenvatinib·Cisplatin

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

Beijing

2025-11-11

Recruiting

BDB-001 Phase III Trial in ANCA-Associated Vasculitis

NCT07168161ANCA Associated Vasculitis (AAV)

DrugsAzathioprine·Prednisone·Rituximab·Cyclophosphamide

Staidson (Beijing) Biopharmaceuticals Co., Ltd

Phase 3

300

Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Meizhou, Shaoguan, Shenzhen

2025-11-10

Recruiting

A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

NCT07181681Solid Tumors, Advanced Solid Tumor

BeOne Medicines

Phase 1

Beijing, Chongqing, Xiamen, Harbin, Zhengzhou, Shanghai, Chengdu, Hangzhou

2025-11-10

Recruiting

A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors

NCT07265921Advanced Solid Cancer

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 1

232

Beijing, Nanjing, Shanghai, Tianjin, Wuhan

2025-11-07

Recruiting

A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)

NCT07261644Ankylosing Spondylitis

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Phase 3

500

Beijing

2025-11-07

Recruiting

Efficacy and Safety of ACC017 Tablets Compared With Dolutegravir Sodium Tablets in Treatment-Naïve Adults With Human Immunodeficiency Virus Type 1 (HIV-1)

NCT07711223Infection, Human Immunodeficiency Virus

DrugACC017

Jiangsu Aidea Pharmaceutical Group Co., Ltd.

Phase 1/2

660

Beijing

2025-11-07

Recruiting

PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis

NCT06902740Intracranial Atherosclerosis, Intracranial Artery Stenosis, Atherosclerotic Plaque

Peking Union Medical College Hospital

Phase 4

300

Beijing, Meizhou, Cangzhou, Qinhuangdao, Shijiazhuang, Tangshan, Harbin, Zhengzhou

2025-11-07

Recruiting

Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction

NCT07110415Coronary Heart Disease, Cardiac Dysfunction

DrugYangxinshi

SPH Qingdao Growful Pharmacetical Co.,Ltd

Phase 4

2,708

Haozhou, Beijing, Chongqing, Lanzhou, Guangzhou, Shantou, Zhuhai, Guilin

2025-11-06

Recruiting

A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray

NCT07259538Chronic Rhinosinusitis (CRS)

VivaVision Biotech, Inc

Phase 1

Beijing

2025-11-06

Recruiting

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

NCT07100080Non-Small Cell Lung Cancer

DrugsIza-bren·Pemetrexed·Cisplatin·Carboplatin

Bristol-Myers Squibb

Phase 2/3

500

Beijing, Chongqing, Fuzhou, Jiangmen, Anyang, Luoyang, Jingzhou, Wuhan

2025-11-05

Active, closed

A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection

NCT07245953Chronic Hepatitis B

DrugsHT-101·HT-102

Suzhou HepaThera Biotech Co., Ltd.

Phase 2

Beijing, Fuzhou, Guangzhou, Qingyuan, Nanning, Zhengzhou, Nanjing, Zhenjiang

2025-11-05

Recruiting

Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

NCT07315854Gastric Cancer (GC), Gastroesophageal Junction Cancer, Advanced Gastric Cancer, Metastatic Gastric Cancer

DrugsIparomlimab and Tuvonralimab·Lenvatinib

Beijing Friendship Hospital

Phase 2

Beijing

2025-11-04

Recruiting

A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse

NCT07223840Smoking

DrugBrenipatide

Eli Lilly and Company

Phase 2

222

Beijing, Chengdu, Chongqing, Hangzhou, Linhai, Ningbo, Shenzhen

2025-11-03

Recruiting

IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

NCT07198841Lung Cancer (Non-Small Cell)

DrugsIBI351·Cetuximab

Guangdong Association of Clinical Trials

Phase 2

Guangzhou, Beijing, Foshan, Nanchang, Nanning, Shijiazhuang

2025-11-03

Recruiting

Effect of the Intelligent Lipid Management Decision-support System on 1-year LDL-C Target Achievement in Ischemic Stroke or TIA Patients Under Evolocumab Treatment in China

NCT07143149Ischemic Stroke, Transient Ischemic Attack (TIA)

Beijing Tiantan Hospital

Not applicable

4,000

Beijing

2025-11-03

Recruiting

Effectiveness of Interventional Therapy for Non-Flow-Limiting Vulnerable Plaques

NCT06855537Coronary Arterial Disease (CAD), Vulnerable Coronary Plaques, Thin-cap fIbroatheroma, Acute Coronary Syndromes (ACS)

Beijing Anzhen Hospital

Phase 4

2,190

Beijing

2025-11-03

Recruiting

RCT of Tocilizumab for Anti-MDA5+DM

NCT07377058Dermatomyositis

DrugsCiclosporin·Tacrolimus·Tocilizumab

Peking Union Medical College Hospital

Not applicable

110

Beijing

2025-11-01

Recruiting

A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined With Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.

NCT06641648Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) Relapse, NK Cell

Peking University First Hospital

Phase 1

Beijing

2025-11-01

By invitation

Retrospective Multicenter Study of Patient-level T1CE/FLAIR MRI Deep Learning to Predict EGFR/ALK Driver Status in NSCLC Brain Metastases With External Validation and Survival Analysis

NCT07373951Non-Small Cell Lung Cancer, Brain Metastases

Ming Yang

Observational

380

Beijing

2025-11-01

Recruiting

A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease

NCT07187440Fabry Disease

Takeda

Observational

200

Hefei, Beijing, Fuzhou, Hangzhou, Shantou, Shenzhen, Shijiazhuang, Harbin

2025-11-01

Recruiting

CONNEctome-guided Navigation for Eloquent-area Tumor Surgery Trial

NCT07657403Brain Neoplasms, Eloquent Area Brain Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Not applicable

200

Beijing

2025-11-01

Recruiting

One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei

NCT07328737Pseudomyxoma Peritonei

Beijing Tsinghua Chang Gung Hospital

Not applicable

132

Beijing

2025-11-01

Recruiting

CAIX PET/ CT Guided Radiation Therapy in CcRCC.

NCT07540260Radiation Therapy, Metastatic Renal Cancer, Recurrent Renal Cell Cancer

Peking University First Hospital

Not applicable

Beijing

2025-11-01

Recruiting

An Exploratory Research on the Efficacy and Safety of Antibacterial Absorbable Dressing in Chronic Non-healing Wounds

NCT07261501Wound Heal, Wound Healing Delayed

Peking University Third Hospital

Not applicable

Beijing

2025-11-01

Recruiting

TAIC FOLFOX for Locally Advanced G/GEJA

NCT07655024Gastric Cancer (Diagnosis), Gastroesophageal Junction Adenocarcinoma

DrugFolfox

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Phase 2

Beijing

2025-11-01

By invitation

Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma

NCT07312578Esophageal Squamous Cell Carcinoma

DrugsAlbumin paclitaxel·Nimotuzumab·Camrelizumab·Cisplatin

Peking University

Phase 2

Beijing

2025-11-01

Not yet open

Dexmedetomidine-Esketamine Combination for Sedation and Analgesia in ICU Patients

NCT06468436Aged, Intensive Care Units, Ventilators, Mechanical, Dexmedetomidine

DrugsDexmedetomidine-esketamine combination·Dexmedetomidine

Peking University First Hospital

Not applicable

1,508

Beijing, Tianjin

2025-11

Not yet open

Sacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity

NCT07241338Hypertension

DrugAmlodipine

Jing Liu

Phase 4

104

Beijing

2025-11

Not yet open

Fengliao Changweikang for Diarrhea-predominant Irritable Bowel Syndrome: N-of-1 Trial

NCT07061184Irritable Bowel Syndrome - Diarrhoea, Traditional Chinese Medicine (TCM), N of 1 Study Design, Efficacy and Safety

Peking Union Medical College Hospital

Phase 4

Beijing

2025-11

Not yet open

A Trial of SHR-4658 in Healthy Volunteers or Volunteers With Elevated Blood Pressure

NCT07230145Heart Failure

Beijing Suncadia Pharmaceuticals Co., Ltd

Phase 1

Beijing

2025-11

Not yet open

Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma

NCT07187960Follicular Lymphoma

DrugsTQB2825·Rituximab

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Phase 3

228

Beijing, Chongqing, Lanzhou, Guangzhou, Guiyang, Haikou, Harbin, Zhengzhou

2025-11

Recruiting

To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome

NCT07208591Acute Respiratory Distress Syndrome (ARDS)

Staidson (Beijing) Biopharmaceuticals Co., Ltd

Phase 3

406

Beijing, Xiamen, Guangzhou, Zunyi, Luoyang, Zhengzhou, Wuhan, Xiangtan

2025-10-31

Recruiting

Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo

NCT07172347Non-segmental Vitiligo

DrugVC005

Jiangsu vcare pharmaceutical technology co., LTD

Phase 2

120

Beijing

2025-10-31

Recruiting

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

NCT07223593Peripheral Arterial Disease

DrugOrforglipron

Eli Lilly and Company

Phase 3

1,205

Beijing, Chengdu, Guangzhou, Harbin, Luoyang Shi, Nanjing, Shanghai, Tianjin

2025-10-31

Recruiting

Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC

NCT07110103SCLC, SCLC, Extensive Stage

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

Beijing, Chongqing

2025-10-31

Recruiting

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

NCT07291037Non-small Cell Lung Cancer (NSCLC)

DrugsDato-DXd·Docetaxel

AstraZeneca

Phase 3

400

Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou

2025-10-31

Recruiting

Evaluation of the Safety and Effectiveness of CHORDS® Cerebral Protection System During TAVR: DUET Trial

NCT07648693Transcatheter Aortic Valve Replacement (TAVR), Cerebral Vascular Accident (CVA)/Stroke

Resonova (Shanghai) Medtech Limited

Not applicable

240

Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanchang, Qingdao

2025-10-31

Recruiting

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

NCT07205822Breast Cancer

DrugDato-DXd

AstraZeneca

Phase 3

100

Beijing, Changsha, Guangzhou, Linyi, Shandong, Wuhan, Zhengzhou

2025-10-30

Not yet open

An Exploratory Study of Golidocitinib in Adult Patients With ITP

NCT07196163Immune Thrombocytopenia (ITP)

DrugGolidocitinib

Peking University People's Hospital

Phase 1/2

138

Beijing

2025-10-30

Not yet open

An Exploratory Study of Near-infrared Light Therapy for Mild to Moderate Alzheimer's Disease

NCT06836180Alzheimer Disease

Xuanwu Hospital, Beijing

Early Phase 1

Beijing

2025-10-30

Recruiting

Dynamic Airway Resistance & ML: Guide Sputum Suction in Ventilated Patients

NCT07375667Mechanical Ventilation Pressure High, Ventilator-Associated Pneumonia (VAP), Respiratory Depression Neonatal

Affiliated Hospital of Nantong University

Not applicable

258

Bengbu, Beijing, Hangzhou

2025-10-30

Recruiting

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

NCT07219615Chronic Spontaneous Urticaria

DrugsLitfulo·Ritlecitinib

Pfizer

Phase 2

200

Beijing, Guangzhou, Shijiazhuang, Shanghai, Tianjin, Hangzhou

2025-10-30

Recruiting

A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT07082192ALS (Amyotrophic Lateral Sclerosis)

Shanghai Zhimeng Biopharma, Inc.

Phase 2/3

240

Beijing

2025-10-30

Recruiting

Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.

NCT07569653Cytomegalovirus Infections, Cytomegalovirus Disease, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease

WeiShi

Phase 4

120

Beijing, Shijiazhuang, Zhengzhou, Jingzhou, Wuhan, Hohhot, Nanchang, Wenzhou

2025-10-30

Recruiting

A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis

NCT07201051Bronchiectasis

DrugGSK3862995B

GlaxoSmithKline

Phase 2

363

Beijing, Chongqing, Dongguan, Guangzhou, Guilin, Hangzhou, Huizhou, Jiangmen

2025-10-30

Recruiting

BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation

NCT07246031Graft -Versus-host-disease, aGVHD, Haploidentical Stem Cell Transplantation, cGVHD

BioPhoenix Co., Ltd.

Phase 2

Beijing, Wuhan

2025-10-29

Active, closed

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease

NCT07220109Respiratory Syncytial Virus Infections

DrugRSVPreF3 OA vaccine

GlaxoSmithKline

Phase 3

750

Beijing, Xiangtan, Nanjing, Chengdu, Chongqing, Guangzhou, Jiujiang, Kunming

2025-10-29

Recruiting

Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis

NCT07192939IPF and PPF

Guangdong Hengrui Pharmaceutical Co., Ltd

Phase 2

270

Beijing

2025-10-29

Recruiting

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

NCT07250269Relapsed/Refractory AL Amyloidosis

DrugAZD0120

Gracell Biotechnologies (Shanghai) Co., Ltd.

Phase 1

Beijing, Changchun, Guangzhou, Hangzhou, Suzhou, Wenzhou, Wuhan

2025-10-29

Recruiting

A Study of Ivonescimab in First-Line ES-SCLC

NCT07245446Extensive-stage Small Cell Lung Cancer (ES-SCLC)

DrugsLigufalimab·Cadonilimab·Ivonescimab·Etoposide

Akeso

Phase 2

180

Beijing, Xi'an, Shanghai

2025-10-29

Active, closed

Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)

NCT07327840Lipoprotein Disorder

Kylonova (Xiamen) Biopharma co., LTD.

Phase 2

204

Beijing, Baotou, Changde, Chongqing, Dali, Daqing, Guangzhou, Harbin

2025-10-29

Recruiting

Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC

NCT07120282Lung Cancer (NSCLC)

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

108

Beijing

2025-10-28

Recruiting

A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor

NCT07140393Solid Tumor

DrugsHRS-4508·Trastuzumab Rezetecan·Pertuzumab·Trastuzumab

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2

120

Beijing

2025-10-28

Recruiting

A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation

NCT07217067Atrial Fibrillation

DrugPKN605

Novartis Pharmaceuticals

Phase 2

165

Beijing, Xi'an

2025-10-28

Recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GB18 Injection in Healthy Participants

NCT07237464Cancer Cachexia (CC), Cancer Cachexia, Cancer Cachexia Syndrome

DrugGB18

Shenzhen Kexing Pharmaceutical Co., Ltd.

Phase 1

Beijing

2025-10-28

Recruiting

Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF

NCT07082842Idiopathic Pulmonary Fibrosis (IPF)

DrugsHEC585·Pirfenidone

Sunshine Lake Pharma Co., Ltd.

Phase 3

472

Beijing

2025-10-27

Active, closed

A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE

NCT07245407Non-cystic Fibrosis Bronchiectasis

AstraZeneca

Observational

251

Beijing, Chongqing, Quanzhou, Lanzhou, Shenzhen, Zhanjiang, Nanning, Guiyang

2025-10-27

Recruiting

A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.

NCT07641634Healthy Volunteers, Systemic Sclerosis (SSc), Scleroderma, Systemic, Scleroderma

Prolium Bioscience, Inc

Phase 1/2

Beijing, Guangzhou, Henan, Nanchang, Nanjing, Pingxiang

2025-10-27

Recruiting

A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis

NCT07499700Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS)

DrugBAT4406F

Bio-Thera Solutions

Phase 2/3

192

Beijing

2025-10-26

Recruiting

TrIal of Early Minimally Invasive Catheter Evacuation With Thrombolysis in IntraCerebral Hemorrhage

NCT07187687Intracerebral Hemorrhage

Xuanwu Hospital, Beijing

Not applicable

750

Guangdong, Baotou, Beijing, Bozhou, Changsha, Changzhi, Changzhou, Chifeng

2025-10-24

Recruiting

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer

DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin

Hoffmann-La Roche

Phase 3

600

Hefei, Nanchang, Hangzhou, Beijing, Bengbu, Changsha, Chengdu, Guangzhou

2025-10-24

Recruiting

Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients

NCT07175155Hypoxemia, Esophageal Cancer, Morbidly Obese Patients, Gastric Cancer

Zhejiang University

Not applicable

410

Beijing, Jinjiang, Hangzhou, Lishui, Taizhou

2025-10-24

Recruiting

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

NCT06899126Non-small Cell Lung Cancer

DrugsTrastuzumab deruxtecan·Pemetrexed·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

686

Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin

2025-10-24

Active, closed

FARAPULSE™ Pulsed Field Ablation System

NCT06762717Paroxysmal AF

Boston Scientific Corporation

Observational

501

Beijing

2025-10-23

Active, closed

A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

NCT07076121Pancreatic Ductal Adenocarcinoma

DrugsNavlimetostat·Abraxane·Nab-paclitaxel·Gemcitabine

Bristol-Myers Squibb

Phase 2/3

470

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Harbin, Luoyang, Zhengzhou

2025-10-23

Recruiting

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

NCT07219173Asthma

DrugBrenipatide

Eli Lilly and Company

Phase 2

531

Baotou, Beijing, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shanghai

2025-10-22

Recruiting

68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer

NCT07508852SCLC, SCLC, Extensive Stage, SCLC, Limited Stage, Small Cell Lung Cancer

Peking University First Hospital

Phase 1/2

Beijing

2025-10-22

Recruiting

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis

DrugsSofe-M·MIRV·Pegylated liposomal doxorubicin·Topotecan

Eli Lilly and Company

Phase 3

1,630

Beijing, Changchun, Changde, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan

2025-10-22

Recruiting

The Research of Integrated Traditional Chinese and Western Medicine on Hypothalamic Amenorrhea

NCT07580950Functional Hypothalamic Amenorrhea

Peking Union Medical College Hospital

Phase 4

210

Beijing

2025-10-22

Recruiting

A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors

NCT07208136Advanced Solid Tumors

Jemincare

Phase 1

102

Beijing

2025-10-22

Recruiting

To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric Junction Adenocarcinoma

NCT07179484Gastroesophageal Junction Adenocarcinoma

DrugCT041 autologous CAR T-cell

Beijing GoBroad Hospital

Observational

Beijing

2025-10-22

Recruiting

SIS-Reinforced vs. Conventional Anastomosis for Mid-to-Low Rectal Cancer: A Multicenter RCT on Anastomotic Leak

NCT07209787Rectal Cancer

Beijing Chao Yang Hospital

Phase 4

966

Beijing

2025-10-21

Recruiting

Phase I Study of CPD704 Inhalation Suspension in Healthy Subjects

NCT07301203Healthy, Healthy Participants

Beijing Tide Pharmaceutical Co., Ltd

Phase 1

Beijing

2025-10-21

Recruiting

Complex Arrhythmia Registry

NCT07024927Atrial Fibrillation (AF), Ventricular Tachycardia (VT)

Beijing Anzhen Hospital

Observational

4,000

Beijing

2025-10-21

Recruiting

A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation

NCT07259590Advanced Solid Tumors Cancer, PDAC, CRC (Colorectal Cancer)

Genfleet Therapeutics (Shanghai) Inc.

Phase 1/2

126

Beijing, Guangzhou, Zhengzhou, Wuhan

2025-10-21

Recruiting

KD Treatment for Super-refractory Status Epilepticus

NCT07496749Super-refractory Status Epilepticus

Xuanwu Hospital, Beijing

Not applicable

Hefei, Beijing, Fuzhou, Nanning, Guiyang, Haikou, Shijiazhuang, Harbin

2025-10-20

Recruiting

Haplo-Cord HSCT for AML/MDS

NCT07588360MDS (Myelodysplastic Syndrome), AML (Acute Myeloid Leukemia)

Fujian Medical University Union Hospital

Not applicable

Fuzhou, Guangzhou, Chengdu, Beijing

2025-10-20

Recruiting

The Efficacy and Safety of Pregabalin Combined With Toludesvenlafaxine in Patients With Fibromyalgia

NCT07208357Fibromyalgia, Pregabalin, Duloxetine, Pain

DrugPregabalin

Beijing Tiantan Hospital

Not applicable

384

Beijing

2025-10-20

Recruiting

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

NCT07177339Pulmonary Disease, Chronic Obstructive

DrugDepemokimab

GlaxoSmithKline

Phase 3

1,196

Shapingba, Nanning, Chengdu, Suining, Beijing, Changchun, Changsha, Chongqing

2025-10-20

Recruiting

Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.

NCT07585981IgA Glomerulonephritis

DrugNefecon

Chinese PLA General Hospital

Observational

Beijing

2025-10-20

Active, closed

A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia

NCT07169331Waldenström's Macroglobulinemia

DrugZanubrutinib

BeiGene

Phase 4

Beijing, Guangzhou, Baoding, Yichang, Changsha, Hangzhou

2025-10-17

Recruiting

A Study of Brenipatide in Participants With Alcohol Use Disorder

NCT07219953Alcohol Use Disorder

DrugBrenipatide

Eli Lilly and Company

Phase 3

1,100

Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei

2025-10-16

Recruiting

A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis

NCT07209761Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis

DrugsPretomanid·Bedaquiline·Linezolid·Moxifloxacin

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 3

532

Beijing, Fuzhou, Shenzhen, Wuhan, Nanjing, Jinan, Shanghai, Chengdu

2025-10-16

Recruiting

Aspirin Continuation or Discontinuation in Conservative Treatment for Chronic Subdural Hematoma

NCT07240454Chronic Subdural Hematoma

Tao Liu

Not applicable

143

Beijing, Tianjin

2025-10-15

Recruiting

Pre-emptive Scalp Infiltration With Low-dose Flurbiprofen and Ropivacaine for Postoperative Analgesia After Craniotomy

NCT07209345Post-craniotomy, Pain

DrugRopivacaine

Beijing Tiantan Hospital

Not applicable

216

Beijing

2025-10-15

Recruiting

A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder

NCT07219966Alcohol Use Disorder

DrugBrenipatide

Eli Lilly and Company

Phase 3

1,100

Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Huzhou

2025-10-15

Recruiting

A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors

NCT07077434Advanced Solid Tumors

DrugNavlimetostat

Bristol-Myers Squibb

Phase 1

Beijing, Fuzhou, Guangzhou, Shenzhen, Harbin, Xinxiang, Jinan, Tianjin

2025-10-15

Recruiting

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

NCT07206056Progressive Metastatic Castrate Resistant Prostate Cancer

DrugLuxdegalutamide

Novartis Pharmaceuticals

Phase 1/2

188

Beijing

2025-10-15

Recruiting

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease

DrugsRetatrutide·Tirzepatide

Eli Lilly and Company

Phase 3

4,500

Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Guiyang

2025-10-15

Active, closed

The Value of Novel Thrombus Markers in the Diagnosis and Treatment of Acute Pulmonary Embolism

NCT06907238Acute Pulmonary Embolism

Beijing Anzhen Hospital

Observational

400

Beijing

2025-10-14

Recruiting

Ventricular Tachycardia：A Registry Study

NCT07149701Ventricular Tachycardia (VT), Structural Heart Disease

Beijing Anzhen Hospital

Observational

1,000

Beijing

2025-10-14

Recruiting

A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

NCT07787182Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid

DrugLY4405094

Eli Lilly and Company

Phase 1

Beijing, Minhang District, Shanghai

2025-10-14

By invitation

A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination

NCT07330440Genital Herpes

Changchun BCHT Biotechnology Co.

Phase 1

144

Beijing

2025-10-13

Recruiting

A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)

NCT07129343Von Willebrand Disease (VWD)

DrugsAdvate·Vonicog Alfa

Takeda

Phase 3

Beijing, Guangzhou, Jihan, Shanghai, Suzhou, Tianjin, Wuhan

2025-10-13

Recruiting

Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma

NCT06932861Rhabdomyosarcoma

Xinxin Zhang

Early Phase 1

Beijing

2025-10-13

Recruiting

Indometacin With or Without Aggressive Intravenous Hydration to Prevent Pancreatitis After Pancreatic Extracorporeal Shock Wave Lithotripsy

NCT07202559Pancreatitis, Chronic, Pancreatitis, Acute, Pancreatic Duct Stones

Changhai Hospital

Not applicable

1,250

Baotou, Beijing, Hangzhou, Hunan, Lanzhou, Shandong, Shanghai, Yunnan

2025-10-13

Recruiting

Balloon Guide Catheter to Optimize Outcomes in Stroke Thrombectomy of the Internal Carotid Artery

NCT07192029Stroke

Xuanwu Hospital, Beijing

Not applicable

364

Fuzhou, Zhangzhou, Beijing

2025-10-12

Recruiting

A Trial to Evaluate the Efficacy, Safety, PK, and PD of HP515 in Non - Alcoholic Fatty Liver Disease ( NASH/MASH )

NCT07308548NAFLD (Non-alcoholic Fatty Liver Disease)

Hinova Pharmaceuticals Inc.

Phase 2

Beijing, Chengdu

2025-10-11

Recruiting

Prospective Study Protocol for Multiparametric PCCT Assessment of Early Ventricular Outcomes After CABG

NCT07883499Coronary Artery Bypass Grafting (CABG) Surgery, Coronary Artery Disease

Xin Lou

Observational

150

Beijing

2025-10-10

Not yet open

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial on the Treatment of Hypertensive Intracerebral Hemorrhage With Naoxuekang Dropping Pills

NCT07200921Hypertensive Intracerebral Hemorrhage, Cerebral Small Vessel Diseases

Beijing Tiantan Hospital

Phase 2

1,950

Beijing

2025-10-10

Recruiting

The Effectiveness of Guided Written Exposure Therapy for Complex PTSD in Adolescents

NCT07325734CPTSD, Compelx Post-traumatic Stress Disorder

Peking University

Not applicable

130

Fuyang, Beijing, Ulanhot, Ürümqi

2025-10-10

Not yet open

A Study to Evaluate the Safety of GR2301 Injection in Healthy Volunteers.

NCT07190716Single Ascending Dose, Healthy Subjects

DrugGR2301

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Phase 1

Beijing

2025-10-10

Recruiting

Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC

NCT07040072HNSCC

Beijing Tongren Hospital

Phase 1

Beijing

2025-10-09

Recruiting

Steroids for Facial Nerve Function Protection in Post-surgical Vestibular Schwannoma Patients

NCT07116811Vestibular Schwannoma, Facial Nerve Paralysis

Beijing Tiantan Hospital

Phase 3

364

Beijing

2025-10-09

Recruiting

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

NCT07140913Mania, Bipolar Disorder

DrugKarXT

Bristol-Myers Squibb

Phase 3

424

Beijing, Guangzhou, Baoding, Shijiazhuang, Changsha, Nanjing, Xi'an, Chengdu

2025-10-08

Active, closed

A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)

NCT07176390Arthritis, Rheumatoid

DrugsTulisokibart·Methotrexate

Merck Sharp & Dohme LLC

Phase 2

185

Beijing, Xiamen, Guangzhou, Xinxiang, Pingxiang, Linfen, Ürümqi, Linhai

2025-10-08

Recruiting

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

NCT07190248Non-small Cell Lung Cancer

Drugs) Berahyaluronidase alfa·Calderasib·Paraplatin·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

675

Hefei, Beijing, Fujian, Fuzhou, Guangzhou, Nanning, Jiamusi, Zhengzhou

2025-10-08

Recruiting

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

NCT07196722Crohn Disease

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 2/3

1,092

Beijing, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou

2025-10-03

Recruiting

Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes

NCT07102628Acute Coronary Syndrome

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

300

Beijing, Guangzhou, Luoyang, Xuzhou, Nanchang, Wenzhou, Fuzhou, Jining

2025-10-03

Recruiting

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma

DrugPonsegromab

Pfizer

Phase 2/3

982

Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Baoding, Langfang

2025-10-03

Recruiting

Light and Anesthesia

NCT07517484Light, Anesthesia, Sedation

Peking University People's Hospital

Not applicable

Beijing

2025-10-03

Active, closed

Early-Life Strategies for Preventing Obesity in Preschool-aged Children

NCT07117149Childhood Obesity Prevention

Peking University

Not applicable

980

Beijing

2025-10-02

Recruiting

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

NCT07207811Transthyretin Amyloid Cardiomyopathy (ATTR CM)

DrugNNC6019-0001

Novo Nordisk A/S

Phase 3

1,280

Hefei, Beijing, Changchun, Fuzhou, Guangzhou, Guiyang, Shijiazhuang, Harbin

2025-10-02

Recruiting

Time to Ambulation After ProGlide Closure

NCT07179536Femoral Access Site Closure, Ambulation, Vascular Access Complication, Vascular Access Site Management

Chinese Academy of Medical Sciences, Fuwai Hospital

Not applicable

300

Beijing

2025-10-01

Recruiting

SV With TTPEE Measurement Predicts Upper Airway Patency in Prolonged Tracheostomy Patients

NCT07107243Tracheostomy

Capital Medical University

Not applicable

300

Hunan, Guangxi, Beijing, Jilin City, Henan

2025-10-01

Recruiting

Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis

NCT07488728EBV-associated T/NK-cell Lymphoproliferative Diseases, Refractory/Relapsed EBV-related Hemophagocytic Lymphohistiocytosis, Letermovir

DrugLetermovir

Beijing Children's Hospital

Not applicable

Beijing

2025-10-01

Not yet open

Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer

NCT07018063Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma, Locally Advanced

DrugsTeysuno·Sintilimab·Nab-paclitaxel·Oxaliplatin

zhoujing

Phase 2

Beijing

2025-10-01

Not yet open

Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor

NCT06556862HR+/HER2- Advanced Breast Cancer

DrugsDalpiciclib·Chidamide

Beijing 302 Hospital

Phase 2

155

Beijing

2025-10-01

Active, closed

Automated Reports Generation of Cardiovascular Magnetic Resonance Imaging

NCT07340762HCM - Hypertrophic Cardiomyopathy

Chinese Academy of Medical Sciences, Fuwai Hospital

Observational

20,000

Beijing

2025-10-01

Active, closed

Exploring the Application of 3D Bioprinting for Personalized Treatment in Primary Liver Cancer With Tumor Microenvironment

NCT07437859Primary Liver Cancer

Peking Union Medical College Hospital

Observational

Beijing

2025-10-01

Active, closed

TNF-α Antagonists Mitigate Systemic Inflammatory Response After Cardiac Arrest.

NCT07176754Cardiac Arrest (CA), Post Cardiac Arrest Syndrome

DrugInfliximab

Peking University Third Hospital

Not applicable

208

Beijing

2025-10-01

Not yet open

High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC

NCT07182708NSCLC (Non-small Cell Lung Cancer), EGFR Activating Mutation, Resectable Lung Non-Small Cell Carcinoma

DrugsFirmonertinib Mesilate·Bevacizumab

Peking University Cancer Hospital & Institute

Phase 2

Beijing

2025-10-01

Active, closed

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

NCT07196748Colitis, Ulcerative

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

896

Beijing, Changzhou, Cheng Du Shi, Chongqing, Foshan, Fuzhou, Guangzhou, Haikou

2025-10-01

Recruiting

Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer

NCT07200141Locally Advanced Rectal Adenocarcinoma

Peking Union Medical College Hospital

Phase 2

156

Beijing

2025-10-01

Active, closed

Obesity Prevention in School-aged Children

NCT07203300Childhood Obesity Prevention

Peking University

Not applicable

1,400

Beijing

2025-10-01

Recruiting

Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Knee Osteoarthritis(OA)

NCT07347028Myofascial Trigger Points, Migraine, Cervicogenic Headache, Chronic Musculoskeletal Pain

Beijing Tiantan Hospital

Not applicable

238

Beijing

2025-10-01

Not yet open

Clinical Trial of Umbilical Cord Mesenchymal Stem Cells in Subacute Ischemic Stroke

NCT07197606Ischemic Stroke

Shanghai IxCell Biotechnology Co., LTD

Phase 2

Beijing

2025-10-01

Active, closed

Microfluidic Urinary Exosome-Based Diagnostic Model for Bladder Cancer

NCT07735858Bladder Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Observational

300

Beijing

2025-10-01

Not yet open

Cofrogliptin and Linagliptin as add-on Therapy to Insulin in Type 2 Diabetes

NCT07198932Type 2 Diabetes

Yanbing Li

Observational

594

Hangzhou, Baoding, Beijing, Shanghai, Xi'an

2025-10-01

Active, closed

Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL

NCT07480863Marginal Zone Lymphoma(MZL)

DrugsEndoxan·Lisaftoclax·Orelabrutinib·Cytoxan

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

Beijing

2025-10-01

Recruiting

Effects of Tracheostomy Decannulation on Respiratory Function

NCT07191509Tracheostomy Decannulation

Capital Medical University

Observational

100

Beijing

2025-10-01

Recruiting

Urokinase for Thrombolysis in Acute Ischemic Stroke

NCT07047326Acute Ischemic Stroke

Capital Medical University

Not applicable

Beijing, Handan

2025-10-01

Recruiting

Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL

NCT07185373Primary Central Nervous System Lymphoma

DrugsTeniposide·Orelabrutinib·Rituximab·Dexamethasone

Huashan Hospital

Phase 2/3

215

Beijing, Chengdu, Fuzhou, Guangzhou, Jinan, Nanchang, Nanjing, Shanghai

2025-10-01

Not yet open

Phase I/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of GC310 Injection in Patients With Wilson's Disease (WD)

NCT07173933Wilson Disease

GeneCradle Inc

Phase 1/2

Beijing

2025-10

Recruiting

A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases

NCT07167537Systemic Sclerosis (SSc), Primary Sjogren's Syndrome

Beijing GoBroad Hospital

Phase 1

Beijing

2025-10

Recruiting

The Efficacy and Safety of Pregabalin and Crisugabalin in Patients With Fibromyalgia

NCT07196657Fibromyalgia, Pregabalin, Pain

DrugsCrisugabalin·Pregabalin

Beijing Tiantan Hospital

Not applicable

1,116

Beijing

2025-09-30

Recruiting

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

NCT07106762Urothelial Cancer

DrugsIza-bren·Gemcitabine·Cisplatin·Carboplatin

Bristol-Myers Squibb

Phase 2/3

470

Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Changsha, Nanjing, Nantong

2025-09-30

Not yet open

Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity

NCT07135141Severe Obesity

Beijing Friendship Hospital

Not applicable

256

Beijing, Changsha, Chengdu, Guangzhou, Jinan, Kunming, Nanjing, Shanghai

2025-09-30

Recruiting

A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

NCT07145151Metabolic Dysfunction-associated Steatohepatitis (MASH)

DrugUBT251

The United Bio-Technology (Hengqin) Co., Ltd.

Phase 2

156

Beijing

2025-09-30

Recruiting

Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation for Postoperative Headache Following Stent-Assisted Coiling of Unruptured Intracranial Aneurysms

NCT07479082Unruptured Intracranial Aneurysm, Headache, Vagus Nerve Stimulations

Beijing Tiantan Hospital

Not applicable

440

Beijing

2025-09-30

Not yet open

A Study of CAR-T Cells in Subjects With Autoimmune Diseases

NCT07040917Autoimmune Diseases

Chinese PLA General Hospital

Early Phase 1

Beijing

2025-09-30

Recruiting

A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

NCT07192614Prostate Cancer

AstraZeneca

Phase 1/2

Beijing, Chengdu, Guangzhou, Nanjing

2025-09-30

Recruiting

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

NCT07202884Urinary Incontinence,Stress

DrugOrforglipron

Eli Lilly and Company

Phase 3

1,000

Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Lanzhou, Nanjing

2025-09-30

Not yet open

A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone

NCT07156500Type 2 Diabetes

DrugOlatorepatide

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 3

204

Beijing

2025-09-30

Not yet open

Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC

NCT07200154Limited-stage Small-cell Lung Cancer, Concurrent Chemoradiation Therapy

Peking University Cancer Hospital & Institute

Phase 2

Beijing

2025-09-30

Recruiting

The Efficacy and Safety of Pregabalin Combined With Dexmedetomidine in Patients With Fibromyalgia

NCT07230197Fibromyalgia, Pregabalin, Dexmedetomidine

DrugPregabalin

Beijing Tiantan Hospital

Not applicable

400

Beijing

2025-09-30

Recruiting

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

NCT07204275Primary Membranous Nephropathy

DrugsPovetacicept·Tacrolimus

Vertex Pharmaceuticals Incorporated

Phase 2/3

176

Baotou, Beijing, Bengbu, Changchun, Changsha, Chengdu, Dalian, Dongguan

2025-09-30

Recruiting

A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting

NCT07022483Endometrial Cancer

DrugTrastuzumab deruxtecan

Daiichi Sankyo

Phase 3

710

Beijing, Changchun, Chengdu, Hangzhou, Jinan, Linyi, Nanchang, Nanning

2025-09-30

Recruiting

A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer

NCT07532434Ovarian Cancer, Breast Cancer

Peking University Third Hospital

Observational

480

Beijing

2025-09-30

Recruiting

Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction

NCT07489534Multiple Myeloma

Daihong Liu

Phase 2

Beijing

2025-09-29

Recruiting

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma

DrugsPF-08046054·Docetaxel

Pfizer

Phase 3

680

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Wuhan

2025-09-29

Recruiting

An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma

NCT07200375Diffuse Large B-Cell Lymphoma

DrugGlofitamab

Hoffmann-La Roche

Observational

300

Langfang, Tianjin, Beijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan

2025-09-29

Recruiting

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate

DrugsMevrometostat·Xtandi·Enzalutamide

Pfizer

Phase 3

1,000

Wuhu, Beijing, Chongqing, Lanzhou, Guangzhou, Wuhan, Changsha, Huai'an

2025-09-28

Active, closed

A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors

NCT07160335Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma

DrugsUS-sourced Keytruda·Pembrolizumab

Shanghai Henlius Biotech

Phase 1

174

Hefei, Wuhu, Beijing, Hunan, Fuzhou, Xiamen, Lanzhou, Cangzhou

2025-09-26

Recruiting

A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)

NCT07133633Radiographic Axial Spondyloarthritis

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 2

315

Bengbu, Beijing, Guangzhou, Luoyang, Pingxiang, Changchun, Ürümqi, Kunming

2025-09-26

Recruiting

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

NCT07129993Urothelial Cancer, Bladder Cancer

DrugsDato-DXd·Gemcitabine·Cisplatin·Carboplatin

Daiichi Sankyo

Phase 2/3

630

Beijing, Chengdu, Guangzhou

2025-09-26

Recruiting

A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

NCT07190196Immunoglobulin G4 Related Disease

DrugRilzabrutinib

Sanofi

Phase 3

124

Beijing, Chengdu, Hangzhou, Jiazhuang, Taiyuan, Wuhan, Yantai

2025-09-26

Active, closed

Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps

NCT07107256Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

DrugTQC2731

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Phase 3

246

Fuyang, Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Shenzhen

2025-09-25

Recruiting

MH-ART vs CF-IMRT in Postoperative Cervical/Endometrial Cancer

NCT07584161Cervical Cancer, Endometrial Cancer

Xiaorong Hou

Not applicable

228

Beijing

2025-09-25

Not yet open

Advancing Assessment for Disorders of Consciousness

NCT07180589Disorders of Consciousness

Xuanwu Hospital, Beijing

Observational

200

Beijing

2025-09-25

Recruiting

PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma

NCT07188610CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase 2

100

Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Suzhou

2025-09-25

Not yet open

A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI

NCT07165418Renal Cell Carcinoma (RCC)

DrugsVorolanib·Sunitinib·Everolimus

Peking University Cancer Hospital & Institute

Phase 3

116

Beijing

2025-09-25

Recruiting

The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE

NCT07185269Systemic Lupus Erythematosus (SLE)

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Phase 1/2

198

Beijing

2025-09-24

Recruiting

Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation 2

NCT07139314Ischemic Stroke, Atrial Fibrillation

Capital Medical University

Not applicable

240

Ma’anshan, Beijing, Zhangzhou, Heyuan, Qinzhou, Baoding, Harbin, Jiamusi

2025-09-24

Recruiting

Saline Contrast Electrical Impedance Tomography Method for Diagnosis of Acute Pulmonary Embolism

NCT07190079Acute Pulmonary Embolism

Peking Union Medical College Hospital

Observational

343

Beijing

2025-09-24

Recruiting

A Prospective, Multi-Center Registry Study of Progressive Pulmonary Fibrosis (PPF) in China (PROFINA)

NCT07683728Progressive Pulmonary Fibrosis

Zuojun Xu

Observational

600

Beijing

2025-09-23

Recruiting

Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects

NCT07150975Obesity/Overweight in Adult

DrugsBofanglutida·Wegovy·Semaglutide

Gan & Lee Pharmaceuticals.

Phase 3

420

Beijing

2025-09-23

Recruiting

Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors

NCT07357623Pulmonary Neuroendocrine Tumor

DrugSurufatinib

Shanghai Chest Hospital

Phase 2

Hefei, Beijing, Zhengzhou, Shanghai

2025-09-22

Recruiting

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib

NCT07164170Non-Small Cell Lung Cancer

DrugsABSK043·Glecirasib

Abbisko Therapeutics Co, Ltd

Phase 2

Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan

2025-09-22

Not yet open

A Post-Market Study of Drug-Coated Peripheral Balloon Dilatation Catheter in Treating Femoropopliteal Artery Stenosis or Occlusive Lesions.

NCT07187128Femoropopliteal Artery Stenoses or Occlusive Lesions

BrosMed Medical Co., Ltd

Not applicable

150

Beijing, Chongqing

2025-09-22

Recruiting

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT07111520Non-small Cell Lung Cancer

DrugsBNT326·Pumitamig

BioNTech SE

Phase 1/2

880

Baoding, Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei

2025-09-22

Recruiting

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

NCT07154264Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

DrugsBirelentinib·Venetoclax

Dizal Pharmaceuticals

Phase 2

Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Yichang, Changsha, Changzhou

2025-09-22

Recruiting

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967Plaque Psoriasis

DrugsUstekinumab·Deucravacitinib

Bristol-Myers Squibb

Phase 3

3,040

Bengbu, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Harbin

2025-09-22

Not yet open

RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction

NCT07166380Transcranial Bone Marrow Injection, RK-4, Acute Large Hemispheric Infarction, Acute Ischemic Stroke

Neurodawn Pharmaceutical Co., Ltd.

Phase 1/2

Beijing

2025-09-20

Recruiting

The Efficacy and Safety of Pregabalin Combined With Venlafaxine in Patients With Fibromyalgia

NCT07186751Fibromyalgia, Pregabalin, Venlafaxine, Pain

DrugPregabalin

Beijing Tiantan Hospital

Not applicable

750

Beijin, Beijing

2025-09-20

Recruiting

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

NCT07157787Primary Membranous Nephropathy

Alexion Pharmaceuticals, Inc.

Phase 2

Baotou, Beijing, Guangzhou, Shenzhen

2025-09-19

Recruiting

A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets

NCT07170800Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis

DrugDelamanid

WestVac Biopharma Co., Ltd.

Phase 2

Wuhan, Changsha, Nanjing, Jinan, Chengdu, Beijing, Shanghai

2025-09-19

Recruiting

Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis

NCT07130604Plaque Psoriasis

DrugD-2570

InventisBio Co., Ltd

Phase 3

390

Beijing

2025-09-18

Recruiting

A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult

NCT07199270Health Adult Subjects

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Phase 1

Beijing

2025-09-18

Recruiting

Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach

NCT07178340Hepatoid Adenocarcinoma of Stomach

Peking University Cancer Hospital & Institute

Phase 2

Beijing

2025-09-18

Not yet open

A Single-arm Phase 2 Prospective Clinical Study of Enatumab in the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia

NCT07190261Autoimmune Hemolytic Anemia

Bing Han

Phase 2

Beijing

2025-09-18

Recruiting

Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases

NCT06848842Colorectal Liver Metastases

DrugIvonescimab

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

Beijing

2025-09-18

Active, closed

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07169578Alzheimers Disease

DrugTrontinemab

Hoffmann-La Roche

Phase 3

1,101

Xuzhou, Shanghai, Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou

2025-09-17

Recruiting

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

NCT07190222Chronic Obstructive Pulmonary Disease

DrugLunsekimig

Sanofi

Phase 3

942

Baotou, Beijing, Changchun, Changde, Changsha, Chengdu, Chongqing, Dalian

2025-09-17

Recruiting

QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma

NCT07049185Esophageal Squamous Cell Carcinoma

DrugLenvatinib

Peking University Cancer Hospital & Institute

Phase 2

Beijing

2025-09-17

Recruiting

JS207 Combination Therapy in Triple-negative Breast Cancer

NCT07045311Triple-negative Breast Cancer

Drugs9MW2821·JS207·Albumin paclitaxel

Shanghai Junshi Bioscience Co., Ltd.

Phase 2

Hefei, Beijing, Guangzhou, Baoding, Harbin, Zhangzhou, Wuhan, Nanjing

2025-09-17

Recruiting

Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML

NCT07172204Intensive Chemotherapy Unfit, Newly Diagnosed Acute Myeloid Leukemia (AML), Age ≥60

First Affiliated Hospital of Zhejiang University

Phase 2

Beijing, Shenzhen, Suzhou, Nanchang, Hangzhou

2025-09-16

Recruiting

NCT07190209Chronic Obstructive Pulmonary Disease

DrugLunsekimig

Sanofi

Phase 3

942

Beijing, Changchun, Changsha, Chengdu, Foshan, Guangzhou, Hangzhou, Harbin

2025-09-16

Recruiting

A Clinical Study of GK02 in Malignant Ascites

NCT07378436Malignant Ascites Caused by Advanced Solid Tumors

Beijing Geekgene Technology Co., LTD

Early Phase 1

Beijing

2025-09-16

Recruiting

LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma

NCT07100067Relapsed/Refractory Multiple Myeloma(MM)

Nanjing Legend Biotech Co.

Not applicable

Beijing, Tianjin, Wuhan

2025-09-16

Recruiting

Exploratory Clinical Study on the Safety of STR-P004

NCT07143617Autoimmune Diseases

DrugSTR-P004

Beijing GoBroad Hospital

Not applicable

Beijing

2025-09-16

Recruiting

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

NCT07091630Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy

DrugEmpasiprubart

argenx

Phase 3

160

Fuzhou, Guangzhou, Beijing, Xi'an

2025-09-16

Recruiting

The Efficacy and Safety of Pregabalin Combined With Desvenlafaxine in Patients With Fibromyalgia

NCT07171320Fibromyalgia, Pregabalin, Pain

DrugPregabalin

Beijing Tiantan Hospital

Not applicable

384

Beijing

2025-09-15

Not yet open

Changes in Body Composition of Patients With Obesity Related Tumors and Their Impact on Clinical Outcomes: a Multicenter Prospective Cohort Study

NCT07161167Obesity Rekated Cancer, Body Composition Changes, Survival, Mechanism

Peking Union Medical College Hospital

Observational

6,743

Beijing

2025-09-15

Recruiting

Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer

NCT07106892Colorectal Cancer (CRC)

DrugsHLX43 3·HLX43 2·HLX43 1

Shanghai Henlius Biotech

Phase 2

Beijing, Jinan

2025-09-15

Recruiting

Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07115485Gastric or Gastroesophageal Junction Adenocarcinoma

DrugsHLX43 3·HLX43 2·HLX43 1

Shanghai Henlius Biotech

Phase 2

Beijing

2025-09-15

Recruiting

The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis

NCT07118319Amyotrophic Lateral Sclerosis (ALS)

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.

Phase 1

Beijing

2025-09-15

Recruiting

TaVNS for Acute Intracerebral Hemorrhage

NCT06918964Intracerebral Hemorrhage

Beijing Tiantan Hospital

Not applicable

186

Beijing

2025-09-15

Active, closed

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

NCT07153471Osteoarthritis

DrugOrforglipron

Eli Lilly and Company

Phase 3

800

Baotou, Beijing, Chongqing, Harbin, Hefei, Jinan, Luoyang, Nanjing

2025-09-15

Not yet open

A Phase III Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis

NCT07146126Seasonal Allergic Rhinitis, SAR

Prime Gene Therapeutics Co., Ltd.

Phase 3

600

Beijing, Lanzhou, Baoding, Cangzhou, Langfang, Shijiazhuang, Daqing, Harbin

2025-09-15

Not yet open

Acupuncture for Anxiety/Depression in Patients With Breast Cancer

NCT07183813Anxiety Depression, Breast Cancer, Acupuncture

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Not applicable

360

Beijing

2025-09-15

Recruiting

A Phase I Study of CREPT-618 in Locally Advanced HCC

NCT07364357Hepatocellular Carcinoma (HCC)

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1

Beijing

2025-09-15

Recruiting

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

NCT07043725HER2-positive Breast Cancer

DrugTQB2102

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Phase 3

544

Bengbu, Hefei, Wuhu, Beijing, Chongqing, Quanzhou, Xiamen, Zhangzhou

2025-09-15

Recruiting

A Cohort Study on Increasing Blood Pressure Benefits in Sleep Apnea Patients After CPAP Treatment

NCT07357272Hypertension (HTN), Sleep Apnea Syndrome, Obstructive

Beijing Anzhen Hospital

Observational

200

Beijing

2025-09-15

Active, closed

A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases

NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases

DrugNerandomilast

Boehringer Ingelheim

Phase 3

414

Beijing, Chengdu, Guangzhou, Hangzhou, Luoyang, Macau, Nanchang, Shanghai

2025-09-13

Recruiting

Individualized Precision Therapy With Ceftobiprole Guided by PK/PD in Geriatric Populations

NCT07127185Ceftobiprole

Chinese PLA General Hospital

Observational

150

Beijing

2025-09-12

Active, closed

Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma

NCT07147361Esophageal Squamous Cell Carcinoma (ESCC), Cervical Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Head and Neck Squamous Carcinoma

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Observational

800

Beijing

2025-09-12

Recruiting

A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets

NCT07124221Hyperprolactinemia

DrugCabergoline

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3

382

Beijing

2025-09-12

Active, closed

ASKC200 for Knee Osteoarthritis Pain

NCT07742852Osteoarthritis (OA) of the Knee, Pain

Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Phase 2

175

Beijing

2025-09-12

Recruiting

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

NCT06926868Breast Neoplasms

DrugsIza-bren·Nab-paclitaxel·Capecitabine·Gemcitabine

Bristol-Myers Squibb

Phase 2/3

600

Hefei, Beijing, Fuzhou, Fyzhou, Xiamen, Lanzhou, Nanning, Harbin

2025-09-11

Recruiting

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

NCT06919965Non-Muscle Invasive Bladder Neoplasms

DrugsErdafitinib·Mitomycin C·Gemcitabine

Janssen Research & Development, LLC

Phase 3

220

Beijing, Chengdu, Guangzhou, Nanjing, Ningbo, Tianjin, Wenzhou, Wuhan

2025-09-10

By invitation

Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma

NCT07520214Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Glioblastom WHO Grade 4

Beijing Neurosurgical Institute

Early Phase 1

Beijing

2025-09-10

Recruiting

Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis

NCT07408024Rheumatoid Arthritis (RA)

DrugTollB-001

Toll Biotech Co. Ltd. (Beijing)

Phase 2

Beijing

2025-09-10

Recruiting

A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

NCT07029828Severe Alopecia Areata

DrugsRitlecitinib higher·Ritlecitinib lower

Pfizer

Phase 3

140

Beijing, Guangzhou, Changsha, Shanghai, Chengdu, Hangzhou

2025-09-10

Recruiting

A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

NCT07174908Non-Small Cell Lung Cancer

DrugsD-1553·IN10018

InxMed (Shanghai) Co., Ltd.

Phase 3

400

Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Gannan, Nanchang

2025-09-10

Recruiting

a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia

NCT07140809Hypertriglyceridemia

Shanghai JMT-Bio Inc.

Phase 1/2

Beijing

2025-09-09

Recruiting

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

NCT06855771Carcinoma, Non-Small-Cell Lung

DrugsNavlimetostat·Iza-bren

Bristol-Myers Squibb

Phase 2

182

Beijing, Xiamen, Nanning, Nanchang, Jinan, Linyi, Hangzhou, Linhai

2025-09-09

Recruiting

A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis

NCT07129382Plaque Psoriasis

Chipscreen Biosciences, Ltd.

Phase 1/2

220

Beijing, Chengde, Shijiazhuang, Shiyan, Jinan, Taiyuan, Xi’an, Hangzhou

2025-09-08

Recruiting

Single-Center, Double-Blind, Randomized, Placebo-Controlled Study on Efficacy and Safety of rTMS (With Precise Localization) in Relieving Motor Symptoms of TD

NCT07173920Tardive Dyskinesia, Repetitive Transcranial Magnetic Stimulation

Peking University Sixth Hospital

Not applicable

Beijing

2025-09-08

Recruiting

A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI)

NCT07136792Renal Anemia of Chronic Kidney Disease

DrugPegmolesatide

Guangdong Provincial People's Hospital

Not applicable

Beijing, Longyan, Zhangzhou, Guangzhou, Meizhou, Shantou, Shaoguan, Zhongshan

2025-09-08

Active, closed

A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy

NCT07305974IgA Nephropathy (IgAN)

DrugRG002C0106

Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.

Phase 2

Beijing

2025-09-08

Recruiting

TCM as an Adjuvant Treatment in Mycobacterium Abscessus Pulmonary Disease

NCT07295938Mycobacterium Abscessus Pulmonary Disease

Shanghai University of Traditional Chinese Medicine

Phase 2

352

Beijing, Guangdong, Hefei, Nanchang, Shanghai

2025-09-08

Not yet open

CPET-based HIIT for MAFLD

NCT07177963Metabolic Dysfunction-Associated Fatty Liver Disease

Tang Yida

Not applicable

Beijing

2025-09-08

Recruiting

A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer

NCT07079228Pancreatic Cancer

DrugsQLS31905·Nab-paclitaxel·Gemcitabine

Qilu Pharmaceutical Co., Ltd.

Phase 3

602

Beijing

2025-09-08

Recruiting

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

NCT07181109High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk

DrugZilebesiran

Alnylam Pharmaceuticals

Phase 3

11,000

Beijing, Binhai, Changchun, Changsha, Chengdu, Chenzhou, Chifeng, Chongqing

2025-09-06

By invitation

The Study of ENB With Ultra-thin Cryobiopsy in the Diagnosis of Peripheral Pulmonary Nodules

NCT07326072Diagnosis

Beijing Chao Yang Hospital

Not applicable

228

Beijing

2025-09-05

Recruiting

A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma.

NCT07099430Advanced Melanoma

DrugsLBL-024·Toripalimab

Nanjing Leads Biolabs Co.,Ltd

Phase 1/2

280

Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Nanjing, Changchun, Jinan

2025-09-05

Recruiting

The Efficacy and Safety of Pregabalin and Mirogabalin in Patients With Fibromyalgia

NCT07157852Fibromyalgia, Pregabalin, Mirogabalin, Pain

DrugPregabalin

Beijing Tiantan Hospital

Not applicable

674

Beijing

2025-09-05

Recruiting

Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease

NCT07148791IgG4 Related Disease, B-cell Mediated Autoimmune Disorders

Chinese PLA General Hospital

Phase 2

Beijing

2025-09-05

Recruiting

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT06973187Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsTacabrutideg·Pirtobrutinib

BeOne Medicines

Phase 3

500

Beijing, Fuzhou, Lanzhou, Guangzhou, Jiangmen, Nanning, Guiyang, Shijiazhuang

2025-09-04

Active, closed

Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation

NCT07139301Ischemic Stroke, Atrial Fibrillation

Capital Medical University

Not applicable

438

Ma’anshan, Beijing, Zhangzhou, Heyuan, Qinzhou, Baoding, Harbin, Jiamusi

2025-09-04

Recruiting

A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)

NCT07137910Chronic Hepatitis B

DrugAHB-137

Ausper Biopharma Co., Ltd.

Phase 2

200

Beijing, Jilin City, Chongqing, Xiamen, Guangzhou, Shenzhen, Nanning, Zhengzhou

2025-09-04

Recruiting

Clinical Study of Cizutamig in Systemic Lupus Erythematosus

NCT07215663Systemic Lupus Erythematosus (SLE)

DrugCizutamig

Candid Therapeutics

Phase 1

Beijing, Guangzhou, Luoyang, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai

2025-09-04

Recruiting

A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

NCT06732323Triple-Negative Breast Cancer (TNBC)

DrugESG401

Qilu Pharmaceutical Co., Ltd.

Phase 3

504

Beijing

2025-09-04

Recruiting

A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects

NCT07099118Non - Alcoholic Steatohepatitis

Sunshine Lake Pharma Co., Ltd.

Phase 1

Beijing

2025-09-03

Recruiting

DIND in Patients With aSAH : Real World Study

NCT07160088Aneurysmal Subarachnoid Hemorrhage (aSAH)

Xuanwu Hospital, Beijing

Observational

10,000

Beijing

2025-09-03

Recruiting

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)

Eli Lilly and Company

Phase 3

10,450

Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chongqing, Daqing

2025-09-02

Active, closed

A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B

NCT07135349Chronic Hepatitis B

Shanghai Argo Biopharmaceutical Co., Ltd.

Phase 2

209

Hefei, Beijing, Sichuan, Chongqing, Fuzhou, Guangzhou, Shenzhen, Zunyi

2025-09-02

Active, closed

A Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study)

NCT06969352Gliomas

DrugVorasidenib

Servier (Tianjin) Pharmaceutical Co. LTD.

Not applicable

Beijing, Qionghai, Chengdu

2025-09-02

Recruiting

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT07164443Metastatic Castration-resistant Prostatic Neoplasms

DrugsJNJ-87189401·Pasritamig

Janssen Research & Development, LLC

Phase 3

1,203

Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Nanjing, Nanning, Nantong

2025-09-02

Recruiting

A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma

NCT07093814Glioblastoma

DrugVRT106

Guangzhou Virotech Pharmaceutical Co., Ltd.

Phase 1/2

Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Zhuhai, Nanning, Jinan

2025-09-02

Recruiting

Clinical Multimodal Surveillance of Respiratory Syndrome Pathogens

NCT07694648Respiratory Tract Infections (RTI), Respiratory Syndrome, Acute, Severe, Acute Respiratory Infections (ARIs)

Huashan Hospital

Observational

2,398

Beijing, Guangzhou, Zhuhai, Shijiazhuang, Harbin, Jiamusi, Shangqiu, Zhengzhou

2025-09-01

Not yet open

Effect of Target Temperature Management on Intestinal Flora and Its Metabolites in Patients With Cardiac Arrest

NCT06974682Cardiac Arrest (CA)

Capital Medical University

Observational

Beijing

2025-09-01

By invitation

TACE Treats Nodular Goiter

NCT07258199Nodular Goiter

Peking Union Medical College Hospital

Not applicable

Beijing

2025-09-01

Recruiting

Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia

NCT07321301B-cell Lymphoma Refractory

Daihong Liu

Phase 2

Beijing

2025-09-01

Not yet open

Novel Thin Bronchoscope Versus Ultrathin Bronchoscope for the Diagnosis of Peripheral Pulmonary Nodules

NCT07135297Lung Cancer (Diagnosis)

Shanghai Chest Hospital

Not applicable

465

Beijing, Zhengzhou, Nanjing, Ningbo, Shanghai

2025-09-01

Active, closed

Machine Learning-Based Prediction of Insulin Resistance in Psoriasis Patients Emphasizing Interpretability

NCT07321288Psoriasis, Insulin Resistance

Chinese PLA General Hospital

Observational

1,265

Beijing

2025-09-01

Recruiting

Prospective Evaluation of Dynamic Serum ProGRP for Treatment Response Monitoring in Ewing Sarcoma

NCT07725783Ewing Sarcoma

Peking University People's Hospital

Observational

100

Beijing

2025-09-01

Not yet open

A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL

NCT07035379Diffuse Large B-Cell Lymphoma (DLBCL)

DrugsTRS005·Prednisolone·Doxorubicin·Cyclophosphamide

Zhejiang Teruisi Pharmaceutical Inc.

Phase 1/2

Beijing

2025-09-01

Recruiting

AI-Driven Dynamic Prediction of Non-Target Lesion Progression After PCI: A Chinese Multicenter Cohort Study

NCT07312318Coronary Heart Disease (CHD)

China-Japan Friendship Hospital

Observational

12,000

Beijing

2025-09-01

Recruiting

The Effect of Perioperative Transcutaneous Electrical Acupoint Stimulation Combined With Traditional Chinese Medicine on Gastrointestinal Function Recovery in Patients Undergoing Abdominal Surgery

NCT07081802ERAS, Traditional Chinese Medication (TCM)

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Not applicable

148

Beijing

2025-09-01

Recruiting

Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia

NCT07512700Acute Monocytic Leukemia

Chinese PLA General Hospital

Phase 2

204

Beijing

2025-09-01

Not yet open

Phrenic Nerve Stimulation for Reducing Ventilation Duration in Acute Cerebral Infarction: A Multicenter Randomized Controlled Trial

NCT07133932Cerebral Infarction, Mechanical Ventilation, Acute Cerebrovascular Accident, Adult

Xuanwu Hospital, Beijing

Not applicable

590

Beijing, Shijiazhuang

2025-09-01

Not yet open

A Study on Cardiopulmonary Exercise Tolerance Standards for Healthy Chinese Population

NCT07108296Oxygen Consumption, Cardiorespiratory Fitness

Affiliated Hospital of Changchun University of Chinese Medicine

Observational

4,620

Beijing, Quanzhou, Guangzhou, Nanning, Daqing, Harbin, Puyang, Zhengzhou

2025-09-01

Recruiting

Efficacy and Mechanisms of Macitentan for Non-Coronary Obstructive Angina

NCT07392281Non-Coronary Obstructive Angina

DrugMacitentan

China-Japan Friendship Hospital

Early Phase 1

Beijing

2025-09-01

Recruiting

Clinical Study of the Pulsed Electric Field Ablation System in Chronic Obstructive Pulmonary Disease

NCT07068438Chronic Bronchitis, COPD (Chronic Obstructive Pulmonary Disease)

Suzhou Hengruihongyuan Medical Technology Co. LTD

Not applicable

210

Hefei, Beijing, Changzhou, Suzhou, Wuxi, Xuzhou, Nanchang, Hangzhou

2025-09-01

Recruiting

Validation of RCC Predicting Model With Emulated-target Trial

NCT07117227Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Tumor Thrombus, Prognosis

Peking University Third Hospital

Observational

4,700

Beijing

2025-09-01

Recruiting

Hemodynamic Effects of Norepinephrine Reduction on Critical Closing Pressure in Distributive Shock

NCT07653659Distributive Shock, Hemodynamic Assessment, Critical Illness

Peking Union Medical College Hospital

Observational

Beijing

2025-09-01

Recruiting

Study of Allogeneic Anti-PSMA CAR-NK Cell for Metastatic Castration-Resistant Prostate Cancer

NCT07156045Prostate Cancer Castration-resistant Prostate Cancer

DrugAnti-PSMA CAR-NK

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Early Phase 1

Beijing

2025-09-01

Recruiting

Lung Recruitment Assessed by 2D/3D-EIT and R/I Ratio in Acute Respiratory Failure Patients With Mechanical Ventilation

NCT07379242Acute Respiratory Failure (ARF)

Peking Union Medical College Hospital

Observational

Beijing

2025-09-01

Recruiting

UBT251 Injection Phase II Clinical Study (CKD)

NCT07134335Obesity &Amp; Overweight, Chronic Kidney Disease

DrugUBT251

The United Bio-Technology (Hengqin) Co., Ltd.

Phase 2

180

Beijing

2025-09-01

Not yet open

Research on Ultrasound Diagnostic Criteria for Intracranial and Extracranial Arterial Serial Stenosis

NCT06947720Ischemic Stroke, Carotid Stenosis

Xuanwu Hospital, Beijing

Observational

700

Beijing

2025-09-01

Not yet open

A Study of Yiqi Yangyin Formula in the Treatment of Primary Sjogren's Syndrome

NCT07145060Primary Sjögren's Syndrome (pSS)

China-Japan Friendship Hospital

Not applicable

105

Beijing

2025-09-01

Recruiting

Artificial Intelligence Used in Screening Adrenal Nodules

NCT07198152Adrenal Incidentalomas, Thoracic CT-scan

Peking University First Hospital

Observational

600

Beijing

2025-09-01

Active, closed

Data Mining of Population Health-sub-health-disease Based on Dynamic System Theory

NCT07375303Sub-healthy

Beijing Friendship Hospital

Observational

380,000

Beijing

2025-09-01

Active, closed

Artificial Intelligence Assisting Transcatheter Mitral Edge-to-Edge Repair

NCT07632794Mitral Regurgitation

Mi Chen

Observational

1,500

Beijing

2025-09-01

Recruiting

Study on the Clinical Efficacy of Transcranial Strong Alternating Current (Hi-tACS) in Patients With Neuroimmune Diseases With Insomnia

NCT07558616Neuroimmune Diseases With Insomnia

Xuanwu Hospital, Beijing

Not applicable

Beijing

2025-09-01

Not yet open

Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer

NCT07088731Cervical Carcinoma

DrugsSintilimab·Nab-paclitaxel·Cisplatin

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

180

Beijing

2025-09

Not yet open

Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors

NCT07142837Advanced Solid Tumor

DrugsGecacitinib·ZG005

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1/2

153

Beijing

2025-09

Not yet open

Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological Malignancies

NCT07110194CD20-positive Hematological Malignancies

DrugTQB2825

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Phase 1

Beijing

2025-09

Not yet open

A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.

NCT06886139CD20-positive Diffuse Large B-Cell Lymphoma

DrugTRS005

Zhejiang Teruisi Pharmaceutical Inc.

Phase 2

139

Beijing

2025-09

Not yet open

Enhanced Recovery After Surgery (ERAS) Pathway in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy

NCT05576766Prostate Cancer, Robot-Assisted Laparoscopic Radical Prostatectomy, Enhanced Recovery After Surgery (ERAS) Protocol, Prehabilitation

Peking University First Hospital

Not applicable

Beijing

2025-09

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=4

Query this register directly

GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,576 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,389 of the 5,576 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 990 have not yet opened recruitment, 1,019 are active but closed to new participants, and 178 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.